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 Protection of Pifithrin-α and Melatonin against Doxorubicin-Induced Cardiotoxicity 
by 
Xuwan Liu 
The current studies were designed to explore the protective effects of pifithrin-α and melatonin 
against doxorubicin-induced cardiotoxicity.  Doxorubicin was injected at a dose of 22.5 mg/kg 
(i.p.) in mice to induce cardiotoxic effects.  Meanwhile, doxorubicin caused a significant 
increase of cardiac cell apoptosis following injection (14.2 ± 1.1% for doxorubicin-5 d vs. 1.8 ± 
0.12% for control, P < 0.01).  Ribonuclease protection assays and Western blot analyses revealed 
that doxorubicin upregulated the p53-dependent genes Bax, BclxL, and MDM2 at least 2-fold.  
p53 was phosphorylated at Ser 15 in mouse hearts 1 h following doxorubicin injection, and p38 
and ERK1/2 MAPKs mediated the phosphorylation of p53.  In addition, caspases-3 and -9 were 
activated 24 h after doxorubicin injection.  A p53 inhibitor, pifithrin-α, inhibited doxorubicin-
induced apoptosis when administered at a dose of 2.2 mg/kg.  Pifithrin-α abolished p53 
transactivation activity but did not influence doxorubicin-induced phosphorylation at Ser 15.  By 
effectively inhibiting the expression of p53-dependent genes, pifithrin-α blocked doxorubicin-
induced activation of caspases-3 and -9, thereby preventing cardiac apoptosis.  In addition, 
pifithrin-α attenuated doxorubicin-induced structural and functional damages, without 
diminishing its anti-tumor efficacy on p53-null PC-3 cancer cells.  The protective effects of 
melatonin and its metabolite 6-hydroxymelatonin on doxorubicin-induced cardiac dysfunction 
were evaluated in an isolated perfused mouse hearts and in vivo doxorubicin-treated mice.  While 
perfusion of mouse hearts with 5 µM doxorubicin for 60 min resulted in a 50% suppression of 
HR×LVDP and a 50% reduction of coronary flow, pre-exposure of hearts to 1 µM melatonin or 
6-hydroxymelatonin eased the cardiac dysfunction.  In addition, administration of melatonin or 
6-hydroxymelatonin (2 mg/kg/d) significantly attenuated doxorubicin-induced cardiac 
dysfunction, myocardial lesions, and cardiac cell apoptosis.  Melatonin and 6-hydroxymelatonin 
significantly improved the survival rate of doxorubicin-treated mice.  Another melatonin analog, 
8-methoxy-2-propionamidotetralin, did not show any convincing protection on either animal 
survival or on in vitro cardiac function, presumably due to its lack of free radical-scavenging 
activity.  Finally, neither melatonin nor 6-hydroxymelatonin compromised the anti-tumor activity 
of doxorubicin in cultured PC-3 cells.  These studies suggest that pifithrin-α and melatonin have 
significant therapeutic potential for patients suffering doxorubicin-induced cardiotoxicity. 
 
 
2 
DEDICATION 
 
 
To my mother and my wife for their love and encouragement 
 
3 
ACKNOWLEDGEMENT 
 
There are many people to thank for making my Ph. D. dream a reality.   
I would first like to thank my major adviser, Dr. Balvin H.L. Chua, for his professional 
guidance, persistent encouragement, and enthusiastic support for my Ph.D. study.  I am indebted 
to other Ph.D. committee members for their help and support as well, especially to Dr. Richard 
M. Kostrzewa, the graduate program coordinator, who gave me much advice, consideration, and 
encouragement throughout my project.  I would also like to thank Dr. Donald B. Hoover, Dr. 
Race L. Kao, and Dr. William Stone for their invaluable suggestions and support. 
I would like to give my sincere gratitude to the faculty and staff in the Cardiovascular 
Research Lab, Cecile Cox Quillen Chair of Geriatrics.  These include Dr. Chu C. Chua, who 
helped me on just about everything during my Ph.D. studies; Dr. Zhongyi Chen and Dr. Jin Ping 
Gao, who helped me greatly on the technical aspects of the in vitro and in vivo cardiac function 
studies; and Mrs. Cathy Landy, who helped me complete my experiments and improve my 
English. 
I would like to thank the faculty, staff, and graduate students of the Department of 
Pharmacology for their generous help, especially Dr. Nae J. Dun, Chairman of the Department of 
Pharmacology.  I am grateful to Mrs. Betty Hughes, Mrs. Trish Donaldson, and Mrs. Lottie 
Winters for their excellent secretarial assistance. 
Many thanks go to Mrs. Judy Whitemore and Mrs. Lou Ellen Miller of Department of 
Pathology for their technical assistance. 
 
4 
CONTENTS 
 
 Page 
 
ABSTRACT ........................................................................................................................ 2 
DEDICATIONS..................................................................................................................... 3 
ACKNOWLEDGEMENT ..................................................................................................... 4 
LIST OF TABLES ................................................................................................................ 10 
LIST OF FIGURES .............................................................................................................. 11 
 
Chapter 
 1. INTRODUCTION ........................................................................................................ 13 
  Cardiotoxicity of Doxorubicin................................................................................... 13 
  Effects of DOX on Cardiac Function.........................................................................  14 
   DOX-Induced Cardiac Dysfunction in Patients .................................................. 14  
   Effects on the In Vivo Cardiac Function of Animals ........................................... 15 
   Effects on Function of Isolated Heart Preparations ............................................. 16 
  Myocardial Ultrastructural Damage .......................................................................... 17 
  Subcellular Effects of DOX....................................................................................... 19 
   Effects on Mitochondria ...................................................................................... 19 
   Effects on SR ....................................................................................................... 20 
  Free Radicals and DOX-Induced Cardiotoxicity....................................................... 21 
   DOX Generates Free Radicals ............................................................................. 21 
   ROS Cause DOX-Induced Cardiotoxicity ........................................................... 23 
   Effects of Antioxidants on DOX-Induced Cardiotoxicity ................................... 24 
  Apoptosis and DOX-Induced Cardiotoxicity............................................................. 26 
5 
   Characteristics and Pathways of Apoptosis ......................................................... 26 
   Roles of p53 in Apoptosis.................................................................................... 28 
   Mitochondria and Bcl-2 Family Proteins............................................................. 30 
   Caspases and Apoptosis....................................................................................... 32 
   DOX Induces Cardiac Cell Apoptosis ................................................................. 33 
  Rationale and Aims.................................................................................................... 34 
 2. MATERIALS AND METHODS .................................................................................. 37 
   Animals and Drug Treatments ................................................................................... 37 
   Animals ............................................................................................................... 37 
   Treatment of DOX, PFT-α, and MAPK inhibitors.............................................. 37 
   Treatment of MEL and Its Analogs ..................................................................... 38 
  Analysis of Apoptosis ................................................................................................ 38 
   DNA Laddering ................................................................................................... 38 
   TUNEL Assay...................................................................................................... 39 
   ISOL Analysis...................................................................................................... 39 
   Cell Death ELISA................................................................................................ 39 
  Analysis of Gene Expression ..................................................................................... 40 
   Isolation of Mouse Heart RNA............................................................................ 40 
   RPA Assay .......................................................................................................... 40 
   SuperArray Analysis............................................................................................ 41 
  Detection of Protein Levels ....................................................................................... 41 
   Protein Extraction ................................................................................................ 41 
   Western Blot Analysis ......................................................................................... 42 
  Electron Microscopy Analysis................................................................................... 42 
  Mouse Survival Study................................................................................................ 43 
  Analysis of Enzyme Activities................................................................................... 43 
   Detection of Myocardial Caspase Activities........................................................ 43 
6 
   Measurement of Serum CPK Activities............................................................... 44 
  Measurement of Serum MEL Concentrations ........................................................... 44 
  Cardiac Function Analysis......................................................................................... 44 
   In Vitro Cardiac Function Analysis ..................................................................... 44 
   In Vivo Cardiac Function Analysis ...................................................................... 45 
  Cell Culture and Treatments ...................................................................................... 46 
  Measurement of Cell Density .................................................................................... 46 
  Statistical Analysis..................................................................................................... 47 
 3. RESULTS ..................................................................................................................... 48 
  DOX-Induced Cardiac Cell Apoptosis ..................................................................... 48 
  Mechanisms of DOX-Induced Apoptosis.................................................................. 50 
   DOX Induces p53 Phosphorylation ..................................................................... 50 
   MAPKs Mediate the Phosphorylation of p53...................................................... 51 
   DOX Upregulates Expression of Apoptosis-Related Genes................................ 53 
   DOX Induces Protein Expression of Apoptosis-Related Genes .......................... 55 
  PFT-α Inhibits DOX-Induced Apoptosis and Cardiotoxicity.................................... 55 
   PFT-α Blocks DOX-Induced Cardiac Cell Apoptosis ........................................ 55 
   Effects of PFT-α on DOX-Induced Phosphorylation of p53............................... 56 
   PFT-α Inhibits DOX-Induced Expression of p53 Target Genes ......................... 57 
   PFT-α Inhibits Protein Expression of p53 Target Genes .................................... 57 
   PFT-α Inhibits Caspase Activation...................................................................... 58 
   PFT-α Attenuates Myocardial Ultrastructural Alterations .................................. 59 
   PFT-α Inhibits DOX-Induced Serum CPK Release ............................................ 60 
   PFT-α Protects against DOX-Induced Cardiac Dysfunction .............................. 61 
   Effects of PFT-α on the Anti-Tumor Activities of DOX .................................... 62 
  MEL Protects the Heart against DOX-Induced Cardiotoxicity and Apoptosis ......... 63 
7 
   MEL and 6-OH MEL Improve Survival of DOX-Treated Mice......................... 63 
   MEL and 6-OH MEL Protect Cardiac Function in DOX-Perfused Mouse Hearts 64 
   Role of MEL1a Receptor in the Cardioprotective Effects of MEL..................... 66 
   Plasma MEL Concentration in MEL-Administered Mice ................................... 67 
   MEL and 6-OH MEL Protect In Vivo Cardiac Function ..................................... 67 
   MEL and 6-OH MEL Protect Myocardial Ultrastructure.................................... 69 
   MEL and 6-OH MEL Attenuate DOX-Induced Elevation of Serum CPK ......... 70 
   MEL and 6-OH MEL Inhibit DOX-Induced Cardiac Cell Apoptosis................. 70 
   Effects of MEL and 6-OH MEL on the Anti-Tumor Potency of DOX............... 72 
 4. DISCUSSION ............................................................................................................... 73 
  DOX Induces Apoptosis in a p53-Dependent Pathway ............................................ 73 
   DOX Induces Cardiac Cell Apoptosis ................................................................. 74 
   Roles of p53 in DOX-Induced Apoptosis............................................................ 75 
   Activation of p53 ................................................................................................. 76 
   ERK1/2 and p38 MAPKs Mediate p53 Phosphorylation .................................... 78 
   Expression of p53 Downstream Genes ................................................................ 79 
  PFT-α Protects the Heart against DOX-Cardiotoxicity Partly Due to Anti-Apoptosis 80 
   Anti-Apoptosis of PFT-α and Protection against DOX-Induced Cardiotoxicity  80 
   PFT-α Blocks DOX-Induced Gene Expression................................................... 81 
   PFT-α Blocks DOX-Activated Caspases ............................................................ 82 
   PFT-α Protects against DOX-Induced Myocardial Damage............................... 82 
   Effects of PFT-α on the Anti-Tumor Potency of DOX ....................................... 83 
  MEL Protects the Heart against DOX-Induced Cardiotoxicity ................................. 84 
   Antioxidant Activities of MEL and Its Protection of Cardiac Function.............. 84 
   In Vivo vs. In Vitro Cardiac Function .................................................................. 86 
   MEL Protects against DOX-Induced Myocardial Lesions .................................. 87 
8 
   Effects of MEL and 6-OH MEL on DOX-Induced Apoptosis and Necrosis ...... 88 
   Effects of MEL or 6-OH MEL on the Potency of DOX...................................... 89 
  Future Directions ....................................................................................................... 89 
 5. SUMMARY AND CONCLUSION .............................................................................. 90 
BIBLIOGRAPHY.................................................................................................................. 91 
APPENDICES ....................................................................................................................... 108 
  APPENDIX A: Components of Krebs-Henseleit Buffer Used in Heart Perfusion ... 109 
  APPENDIX B: Abbreviations ................................................................................... 110 
VITA    ........................................................................................................................ 112  
9 
LIST OF TABLES 
 
TABLE Page 
 
 1. Summary of Inhibitors Used in the Study  ..................................................................  38 
 2. Antibodies Used in the Study .....................................................................................  42 
 3. Effects of PFT-α on DOX-Induced Cardiac Dysfunction ..........................................  62 
 4. Effects of MEL, 6-OH MEL, and 8-M-PDOT on the Mortality of DOX-Treated Mice 64 
 5. Effects of MEL and 6-OH MEL on the In Vivo Cardiac Function in DOX-Treated Mice 68 
 6. Components of Krebs-Henseleit Bicarbonate Buffer ..................................................   112 
 
10 
 LIST OF FIGURES 
 
FIGURE Page 
 
1. DOX Generates Free Radicals Through Enzymatic Pathways.......................................... 22 
2. Structures of Melatonin and Its Analogs .......................................................................... 25 
3. Domain Structure of Human p53 Protein ......................................................................... 29 
4. Structure of Pifithrin-α ..................................................................................................... 30 
5. Hypothesized Mechanisms of DOX-Induced Apoptosis and Cardiotoxicity .................... 36 
6. DNA Laddering Formation in Mouse Hearts Following DOX Injection .......................... 48 
7. DOX-Induced Cardiac Cell Apoptosis as Analyzed by TUNEL....................................... 49 
8. ISOL Assay Showing DOX-Induced Apoptosis in Mouse Hearts ................................... 49 
9. Phosphorylation of p53 at Ser 15 and Elevation of p53 Levels in DOX-Treated Mouse  
  Hearts ........................................................................................................................ 50  
10. Phosphorylation of p38 and ERK1/2, but not JNK MAPK, in DOX-Treated Mouse  
  Hearts ........................................................................................................................ 51  
11. Effects of MAPK Inhibitors on the Phosphorylation of MAPKs and p53 ..................... 52 
12. Upregulated mRNA Levels of Apoptosis-Related Genes in Mouse Hearts Following  
  DOX Treatment ......................................................................................................... 53 
13. SuperArray Analysis Showing Gene Expression of Apoptosis-Related Proteins ........... 54 
14. DOX-Induced Protein Expression of p53 Target Genes.................................................. 55 
15. Effects of PFT-α on DOX-Induced Apoptosis In Mouse Hearts .................................... 56 
16. Effects of PFT-α on the Phosphorylation of p53 at Ser 15 in DOX-Treated Mouse Hearts 56 
17. Inhibitory Effects of PFT-α on the Expression of p53 Target Genes in DOX-Treated  
  Mouse Hearts .............................................................................................................  57 
11 
18. Effects of PFT-α on the Protein Expression of Apoptosis-Related Genes...................... 58 
19. PFT-α Blocked DOX-Induced Activation of Caspases-3 and -9 .................................... 59 
20. PFT-α Protected against DOX-Induced Myocardial Ultrastructural Alterations............ 60 
21. Inhibition of DOX-Induced Elevation of Serum CPK..................................................... 61 
22. Effects of PFT-α on the Anti-Tumor Potency of DOX ................................................... 63 
23. Effects of MEL, 6-OH MEL, and 8-M-PDOT on the Cardiac Function of DOX-Perfused 
Mouse Hearts ............................................................................................................. 65 
24. Effects of MEL, 6-OH MEL, and 8-M-PDOT on DOX-Induced Reduction of 
  Coronary Flow ........................................................................................................... 66 
25. Effects of MEL on the Cardiac Function and Coronary Flow in DOX-Perfused Hearts of 
  MEL1a Receptor-Deficient Mice .............................................................................. 67 
26. Representative Electron Micrographs Showing Morphological Alterations of Hearts  
  From Treated Mice .................................................................................................... 69 
27. MEL and 6-OH MEL Protected DOX-Induced CPK Release......................................... 70 
28. Protective Effects of MEL or 6-OH MEL on Apoptosis in DOX-Treated Mouse Hearts 71 
29. Protective Effects of MEL and 6-OH MEL on DNA Fragmentation.............................. 71 
30. Effects of MEL and 6-OH MEL on the Growth of PC-3 Cells ....................................... 72 
 
 
12 
CHAPTER 1 
INTRODUCTION 
 
Cardiotoxicity of Doxorubicin 
 Doxorubicin (DOX) and other anthracycline anti-tumor antibiotics are a group of 
glycosidic antibiotics isolated from cultures of Streptomyces peucetius var. caesieus in the 1960s 
(Arcamone and others 1969; Di Marco and others 1969).  Their discovery represented a major 
breakthrough in the fight against human cancers, as the drug was found to be unusually potent in 
a variety of malignancies.  Today, DOX and other anthracycline antibiotics remain as major 
weapons in the combat of human malignant diseases (Davis and Davis 1979; Rinehart and others 
1974).  Owing to its broad anti-tumor spectrum and high potency, DOX is currently a first-line 
drug in the chemotherapy of a variety of hematopoietic tumors such as leukemias and solid 
tumors including breast and ovarian cancers, lymphomas, sarcomas, and gastrointestinal 
neoplasm (Hortobagyi 1997).  In fact, all malignancies except colon cancer are responsive to 
DOX therapy (Davis and Davis 1979).   
 Unfortunately, DOX and other anthracyclines induce a number of side effects.  In 
addition to common side effects of cancer chemotherapy such as nausea, vomiting, alopecia, 
nasal and oral mucosal ulceration, and hematopoietic depression due to inhibition of dividable 
cells (Creasey and others 1976), DOX induces a unique cardiotoxicity leading to drug-resistant 
congestive cardiac failure (Rinehart and others 1974; Bristow and others 1978).  Indeed, it has 
been found that the incidence of cardiac failure increases abruptly in patients receiving more than 
500 mg/m2 of DOX, a fact that significantly limits DOX’s application as a therapeutic agent.   
 Over the past three decades, DOX-induced cardiotoxicity has been extensively 
investigated, and various studies have been performed to minimize the cardiac side effects of 
DOX administration.  In clinical studies, researchers have attempted to optimize the 
administration schedule of DOX.   In one study, cardiac toxicity was partly reduced on a weekly 
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therapy instead of the conventional once every 3 week injection (Torti and others 1983).  In 
contrast, another study suggested that 500 mg/kg is a risk-cumulative dose in patients (Lefrak 
and others 1973; Billingham and others 1978).  Thus, it is still uncertain which dosage to use for 
DOX administration.  In terms of potential treatments, various interventions based on reducing 
the number of free radicals produced by DOX have displayed some encouraging effects, but this 
research is far from being complete.  In the end, DOX-induced cardiotoxicity remains an 
important issue, and the optimal strategy for its prevention has yet to be defined. 
  
Effects of DOX on Cardiac Function 
The cardiotoxicity of DOX has been subdivided into acute and chronic effects, depending 
on their occurrence following administration of the drug.  Cardiac dysfunction is one of the most 
important features in both acute and chronic cardiotoxicity.  It occurs in humans, animal models, 
and isolated heart preparations after exposure to DOX.   
 
DOX-Induced Cardiac Dysfunction in Patients 
 Acute cardiotoxic effects of DOX include hypotension, tachycardia, pericarditis-
myocarditis syndrome, left ventricular dysfunction, and various arrhythmias, which develop 
within minutes after DOX administration (Bristow and others 1978; Ferrans 1978).  The 
hypotensive effect is believed to be the consequence of peripheral vascular dilatation, caused by 
DOX-induced release of histamine and catecholamines (Bristow and others 1983).  The 
pericarditis-myocarditis syndrome tends to affect patients either with or without a previous 
history of cardiac disease.  Pericarditis can occur alone, but most patients exhibited pericarditis 
accompanied by significant myocardial dysfunction; in some cases, these patients died of 
cardiogenic shock (Starkebaum and Durack 1975).   
In contrast to the acute cardiotoxic effects of DOX, chronic DOX-cardiotoxicity develops 
several weeks or months after treatment, sometimes even having its onset after the course of 
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therapy has been completed.   These delayed effects manifest as cardiomyopathy or as an 
insidious onset of congestive cardiac failure (Henderson and others 1978).  Although some 
studies have shown that heart failure is directly related to the amount of myocyte damage that 
can be evaluated by endomyocardial biopsy (Bristow and others 1978), others have found that 
cardiac dysfunction is not perfectly proportional to myocardial morphological changes (Isner and 
others 1983).  Therefore, it is difficult to accurately predict the severity of DOX-induced 
cardiotoxicity based on the endomyocardial biopsy.   
There seems to be a relationship between the occurrence of cardiac failure and the 
cumulative dose of DOX.  When patients receive cumulative doses of DOX higher than 500 
mg/m2, the incidence of cardiac failure reaches 30-50% (Lefrak and others 1973).  Certain 
changes in the drug administration schedule, such as reducing the acute dose and increasing 
injection frequency (thus keeping the cumulative dose unchanged), have been shown to partly 
suppress the cardiotoxicity of DOX (Torti and others 1983).  This suggests that the development 
of chronic cardiomyopathy is related to the acute peak drug levels.  Thus, acute and chronic 
cardiotoxicity could be induced by the same mechanism. 
 
Effects on the In Vivo Cardiac Function of Animals 
 Cardiotoxicity has been successfully induced in DOX-injected animals including mice, 
rats, rabbits, and dogs (Rosenoff and others 1975; Doroshow and others 1979; Unverferth and 
others 1985).  In one study, DOX injection decreased cardiac output and left ventricular (LV) 
peak systolic pressure in rats within a few hours by 42% and 36%, respectively (Luo and others 
1997).  In another study, systolic and diastolic LV functions were decreased progressively in 
dogs after multiple injections of DOX (1 mg/kg/wk for 8 wk, then 1 mg/kg every other wk for 
another 8 wk); after 16 wk of DOX treatment, maximum systolic dP/dt and cardiac index were 
decreased by 25% and 40%, respectively, whereas left ventricular end-diastolic pressure 
(LVEDP) was increased 250% (Unverferth and others 1985).  While diastolic dysfunction may 
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be an earlier sign of DOX-induced cardiotoxicity than systolic dysfunction, high doses of DOX 
produce both systolic and diastolic dysfunctions.  Furthermore, cardiac dysrhythmia is 
sometimes observed in DOX-treated animals, but it is more difficult to study due to its 
paroxysmal nature.  DOX-induced cardiac dysrhythmia in dogs ranges from acute tachycardia to 
delayed development of persistent atrial and ventricular ectopic dysrhythmias together with 
variable depression of atrial-ventricular conductance (Kehoe and others 1978).  The severity of 
the rhythm changes does not appear to be directly dose-dependent.  Overall, DOX-induced 
cardiac dysfunctions during in vivo animal studies are similar to the dysfunction characteristics 
of DOX-induced cardiotoxicity in patients. 
 
Effects on Function of Isolated Heart Preparations 
DOX impairs cardiac contractility, relaxation, and compliance in isolated animal hearts 
as a Langendorff preparation at various concentrations (Pelikan and others 1986; Chen and 
others 1987; Pouna and others 1996; Platel and others 1999).  The magnitude of cardiac 
dysfunction depends on the duration and dose of DOX administration.  In isolated rat hearts 
perfused with 10 µM DOX, left ventricular developed pressure (LVDP) increased slightly at 30 
min and steadily decreased thereafter to 76% at 70 min; in contrast, LVEDP increased 5-fold 
after 70 min of perfusion (Pelikan and others 1986).  Elevated coronary resistance during DOX-
perfusion could result in myocardial under-perfusion and dysfunction.  In non-paced isolated 
hearts, perfusion of DOX induces a 30% decline in heart rate after 30-min perfusion (Ganey and 
others 1991). Apart from the isolated whole heart, other isolated cardiac preparations have also 
been used.  For instance, in isolated heart papillary muscle preparations, DOX dose-dependently 
causes suppression of both positive and negative rate of force development (±dP/dt) and 
increased lipid peroxidation at a dose range of 10 µM to 1 mM, although these doses are much 
higher than the serum peak levels in DOX-administered patients (Lee and others 1991).  In 
isolated atria preparations, DOX inhibits both contraction frequency and contractile forces at a 
16 
dose of 0.1 mM, but overexpression of catalase in mouse hearts greatly attenuates these effects.  
These studies suggest that free radicals play important roles in DOX-induced cardiac dysfunction 
(Kang and others 1996). 
The relationship between DOX’s effects on isolated cardiac preparations and its clinical 
cardiotoxicity is unclear, since a single dose of DOX rarely causes heart failure in patients, 
whereas acute exposure to DOX predictably causes dysfunction of isolated preparations.  
Furthermore, the concentrations required to initiate dysfunction in isolated heart preparations are 
10- to 100-fold higher than plasma concentrations of DOX (0.1 µM) in patients receiving 
chemotherapy (Benjamin and others 1977; Pelikan and others 1986).  Nevertheless, DOX-
induced dysfunction in isolated heart preparations resembles the cardiac dysfunction of in vivo 
animal studies in many aspects.    The isolated heart preparation has provided evidence of free 
radical generation related to its cardiac dysfunction, and it may provide more insights into DOX-
induced cardiotoxicity. 
 
Myocardial Ultrastructural Damage 
The decrease in number of cardiac myocytes has been described in the postmortem of 
cancer patients administered DOX soon after its clinical application (Lefrak and others 1973).  
Further studies indicate that ultrastructural changes are dose-related as well as time-related and 
that ultrastructural changes persist even months after DOX administration (Jaenke 1974).  The 
earliest change following DOX-treatment in the human heart is sarcoplasmic vacuolization, 
which appears to be due to the swelling of the myocyte tubular system (Unverferth and others 
1981).  Subsequently, the vacuolar degeneration spreads to form large spaces in the cytoplasm, 
eventually leading to destruction of myofibrils and other structures.  Mitochondrial damages, 
such as swelling, vacuolization, and disruption of cristae, have also been observed (Doroshow 
and others 1985).  Studies of endomyocardial biopsies from patients indicate that pathological 
damage is progressive and could be graded according to changes observed under the electron 
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microscope (Billingham and others 1978; Mason and others 1978).  The changes are graded on a 
scale of “0” to “3” according to Billingham et al., where “0” is defined as no change from 
normal; “1” as scanty cellular changes showing early myofibrillar loss or swelling of the 
sarcoplasmic reticulum (SR) or both; “2” as groups of cells affected with loss of contractile 
elements and vacuolization of the cytoplasm; and “3” as diffuse cell damages with marked 
changes (total loss of contractile elements, loss of organelles, mitochondrial and nuclear 
degeneration). 
Early and late cardiac morphological changes have been fully investigated in numerous 
studies (Lambertenghi-Deliliers and others 1976; Van Vleet and others 1980).  Mitochondrial 
damage with focal clumping of cristae, densification or swelling of the matrix, and the 
development of nucleolar segregation were found in mice 24 h after DOX administration 
(Merski and others 1976).  A larger number of cells are involved and contain dilation of SR 
cisternae, extending to all intracellular compartments within 1 to 2 wk.  Mitochondrial damage 
was not found 1 to 3 months after DOX injection; only sarcoplasmic vacuolization, loss of 
myofibrils and disruption of sarcomeres and intercalated disc existed in a number of cardiac 
myocytes (Bellini and Solcia 1985).  This is different from alterations in hearts from rats and 
rabbits, in which mitochondrial damages have been consistently observed following DOX-
treatment (Jaenke 1974; Doroshow and others 1979; Unverferth and others 1985).  The chronic 
cardiomyopathy may represent the cumulative damages that result from repeated acute drug 
exposures; however, histopathological findings are almost the same in mice receiving single dose 
and multiple dose injections (Bellini and Solcia 1985).  Although clinical studies indicate that 
histopathological damage does not correspond very well to the severity of cardiac dysfunction 
(Isner and others 1983), it is still used as a marker of DOX-induced cardiotoxicity.  The 
histopathological damage is believed to result from DOX-generated reactive oxygen species 
(ROS), since the damage is dramatically attenuated or prevented by co-administration of the 
antioxidant probucol (Singal and others 1995), co-administration of the ion chelator dexrazoxane 
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(Della and others 1996), or the overexpression of endogenous antioxidants such as catalase, 
metallothionein, or manganese superoxide dismutase (MnSOD) (Kang and others 1996; Yen and 
others 1999; Sun and others 2001).  
 
Subcellular Effects of DOX 
 In addition to ultrastructural alterations, dysfunction of SR and mitochondria occurs in 
hearts from DOX-treated animals.  SR releases, sequesters, and stores calcium that determines 
both systolic and diastolic cardiac function of cardiac myocytes; thus, SR dysfunction leads to 
pronounced cardiac dysfunction.  Mitochondrion is the energy metabolic center of oxidative 
phosphorylation and ATP synthesis.  As such, injury to these organelles will inevitably induce 
cardiac contractility impairment. 
 
Effects on Mitochondria 
 DOX-induced mitochondrial dysfunction plays a central role in its cardiotoxicity.  Heart 
mitochondria isolated from rats treated with DOX for 4 to 8 wk show cristae damage, swelling, 
and decrease of Ca2+ loading capacity (Zhou, Starkov, and others 2001).  DOX also inhibits 
respiration of isolated mitochondria dose-dependently (Gosalvez and others 1974).  The damage 
of mitochondrial function is related to the downregulation of adenine nucleotide translocase-1, a 
protein located in the inner mitochondrial membrane that plays a key role in aerobic energy 
metabolism and regulation of mitochondrial membrane pore transition in cardiac myocytes 
(Jeyaseelan and others 1997).  DOX may also impair the cardiac mitochondrial DNA that 
encodes some important enzymes in the mitochondria.  Studies have shown that DOX induces 
breaking of the mitochondrial DNA helix and slows down mitochondrial DNA synthesis (Ellis 
and others 1987).  Mitochondrial DNA deletion, therefore, might occur in the hearts of rats or 
mice chronically treated with DOX (Adachi and others 1993; Serrano and others 1999).  The 
incidence of mitochondrial DNA deletion increases with the dosage and duration of DOX 
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administration, and it can be decreased by co-administration of the antioxidant coenzyme Q10, 
suggesting that ROS are involved in the DNA deletion.  Indeed, it is believed that mitochondrial 
DNA damage results from hydroxyl radicals reacting with mitochondrial DNA to cause the 
preferential hydroxylation of deoxyguanosine at C8, since mitochondria are deficient in DNA 
repair enzymes (Palmeira and others 1997). 
 
Effects on SR 
 SR has two primary functional sites: longitudinal tubules and terminal cisternae.  
Longitudinal tubules sequester and transport Ca2+ to terminal cisternae, where Ca2+ is stored for 
subsequent release to the contractile apparatus.  The release of Ca2+ from the terminal cisternae is 
itself triggered by an increase in intracellular Ca2+.  Chronic DOX-treatment impairs SR function 
(Shadle and others 2000; Boucek, Jr. and others 1987), and such functional impairments are 
associated with decreased expression of the ryanodine receptor, a calcium-induced calcium 
release channel in cardiac SR (Dodd and others 1993).  Some studies have found that DOX 
suppresses SR Ca2+-ATPase and Ca2+ uptake capacity by selectively inhibiting their gene 
expression.  The inhibitory effects of DOX on SR Ca2+-ATPase gene transcription is mediated 
by DOX-generated H2O2 as well as by the downstream up-regulation of Erg-1 gene via ERK 
mitogen-activated protein kinases (MAPK) (Arai and others 1998; Arai and others 2000).  Other 
studies indicate that DOX stimulates Ca2+ release from SR and selectively opens Ca2+ channels 
localized in terminal cisternae, but it has no effects on the SR Ca2+ pump or the contractile 
apparatus.  This suggests that DOX might decrease cardiac contractility by interfering with Ca2+ 
release (Zorzato and others 1985).  Moreover, enzyme activities of adenyl cyclase and guanyl 
cyclase were inhibited at high doses in isolated SR preparations, which was believed to be the 
consequence of free radical generation and lipid peroxidation (Lehotay and others 1983; Singal 
and Pierce 1986).  Therefore, DOX might inhibit the gene expression of key enzymes in the SR 
and disturb Ca2+ handling by induction of ROS. 
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Free Radicals and DOX-Induced Cardiotoxicity 
 As discussed above, many effects of DOX on the myocardium are related to the 
formation of ROS.  The mechanism of DOX-induced cardiac injury has been an active area of 
investigation in the past three decades.  It is believed that the cardiotoxicity of DOX is mediated 
by mechanisms distinct from those responsible for its anti-tumor effects, such as DNA 
intercalation and interference with the activities of DNA topoisomerase II (Keizer and others 
1990; Minotti and others 1999).  Several hypotheses have been suggested to explain the acute 
and chronic cardiotoxicity of DOX.  These include formation of free radicals, inhibition of 
enzymes and proteins, changes in cardiac muscle gene expression, alterations of mitochondrial 
membrane function, impaired Ca2+ handling in SR, mitochondrial DNA damage and dysfunction, 
and induction of apoptosis (Myers and others 1977; Kim and others 1989; Ito Hiroshi 1990; Arai 
and others 1998; Arola and others 2000; Tokarska-Schlattner and others 2002).  The role of free 
radicals in DOX-induced cardiotoxicity has been extensively studied and is accepted by most 
researchers.  The current study aims to test the protective effects of antioxidants on this 
cardiotoxicity. 
 
DOX Generates Free Radicals 
The free radical generation theory in DOX-induced cardiotoxicity is well documented in 
the literature.  Several lines of evidence indicate that DOX generates free radicals via enzymatic 
pathways in cardiac myocytes.  As shown in Fig. 1, DOX is composed of a quinone-form 
aglycone group and an amino sugar group (Fig. 1A).  The quinone moiety can be reduced to a 
semiquinone form (i.e., a free radical) by single electron donors, such as NADPH, cytochrome P-
450 reductase, and NADH and NADH dehydrogenase (Fig. 1B).  This has been shown to occur 
in liver microsomes, cardiac mitochondria, cultured cardiac myocytes, and rat hearts in 
numerous studies (Benjamin and others 1977; Bachur and others 1979; Doroshow 1983; 
Doroshow and Davies 1986; Davies and Doroshow 1986; Lee and others 1991; Sarvazyan 1996).  
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Once formed, the semiquinone transfers an electron to molecular oxygen, generating a 
superoxide anion when it cycles back to the quinone form. 
 
 
A B 
Fig 1. DOX generates free radicals through enzymatic pathways.  A, structure of DOX; B, DOX-
induced free radicals via enzymatic pathways and antioxidant defense systems.  NAD, 
nicotinamide adenine dinucleotide; NADH, reduced NAD; NADP, nicotinamide-adenine 
dinucleotide phosphate; NADPH, reduced NADP; GPx, glutathione peroxidase; GSSG, 
glutathione; GSH, reduced glutathione; SOD, superoxide dismutase. 
 
Free radicals may also be generated via non-enzymatic mechanisms involving DOX and 
iron interactions.  The Fe3+ associates with the ketone and hydroxyl groups of C-11 and C-12 of 
DOX (Fig. 1A), followed by an internal redox reaction, wherein an electron flows from the C-14 
hydroxyl group to iron, generating an Fe2+-DOX free radical complex.  This complex reduces 
oxygen to a superoxide anion, after which an electron flows from Fe2+ to DOX, resulting in an 
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Fe3+-DOX free radical complex.  The complex is then rearranged to Fe2+-DOX (aldehyde), 
which is oxidized to Fe3+-DOX (aldehyde) as another molecule of oxygen is reduced to a 
superoxide anion (Zweier 1985).  Based on this theory, an iron-chelator, dexrazoxane, has been 
tested and has displayed convincing protective effects in both acute and chronic cardiotoxicity 
models (Voest and others 1994; Della and others 1996).  It is believed that the protective effects 
are due to the interference of dexrazoxane with the DOX-iron complex (Malisza and Hasinoff 
1996).   
 
ROS Cause DOX-Induced Cardiotoxicity 
While ROS have been recognized to play important roles in DOX-induced cardiotoxicity, 
questions have been raised regarding how DOX-generated ROS selectively attack the heart, 
rather than other organs.  Studies in mice indicate that the heart has relatively low levels of 
endogenous antioxidant enzymes superoxide dismutase (SOD) and catalase, compared to their 
amounts in the liver (Doroshow and others 1980).  As such, the heart is more vulnerable to 
DOX-generated ROS insults.  Several other factors should not be ignored.  First, DOX-generated 
superoxide anions may be converted to hydrogen peroxide by superoxide dismutase.  When 
DOX is incubated with isolated mitochondria from rat hearts, substantial amounts of superoxide 
anions are formed, accompanying the damage of mitochondrial function (Doroshow 1983).  
Superoxide anions may also be converted to more toxic hydroxyl radicals through the Fenton 
reaction in the presence of Fe2+ (Gille and Nohl 1997).  On the other hand, the peroxynitrite 
(ONOO-) is believed to be formed from the instantaneous reaction of superoxide anion and nitric 
oxide, since nitrotyrosine was observed in mouse hearts following DOX treatment (Weinstein 
and others 2000).  Both hydroxyl radicals and peroxynitrite are highly cytotoxic ROS; they can 
initiate protein oxidation, lipid peroxidation, and membrane damages in cardiac myocytes.  For 
instance, peroxynitrite results in modification of protein-bound tyrosine to 3-nitrotyrosine, 
potentially leading to the malfunction of proteins (Beckman and Koppenol 1996).  Studies have 
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shown that lipid peroxidation occurs in DOX-treated hearts.  The malondialdehyde (MDA), a 
lipid peroxidation product, was increased in isolated rat LV papillary muscles exposed to 100 
µM DOX for 60 min (Lee and others 1991).  The serum creatine phosphokinase (CPK) and 
cardiac troponin T (cTnT) were elevated in DOX-treated patients and experimental animals as 
well (O'Brien and others 1997; Herman and others 1998; DeAtley and others 1999).  Moreover, 
free radicals can impair sequestration of Ca2+ by the SR.  For example, Ca2+ sequestration was 
inhibited by 70% in rat cardiac SR pre-incubated for 30 min with DOX and NAD/NADH 
dehydrogenase; the inhibitory effects were attenuated by incubation with catalase and free 
radical scavengers, N-acetylcysteine and glutathione (Harris and Doroshow 1985).  The role of 
ROS in DOX-induced cardiotoxicity has been recently further supported by experiments using 
transgenic technology.  DOX-induced cardiotoxicity can be largely suppressed by the 
overexpression of antioxidant enzymes MnSOD, metallothionein, or catalase in mouse hearts 
(Yen and others 1996; Kang and others 1997; Kang and others 2002).  In summary, ROS play 
pivotal roles in DOX-induced cardiotoxicity, and antioxidants may minimize the cardiac injury 
induced by DOX-generated ROS. 
 
Effects of Antioxidants on DOX-Induced Cardiotoxicity 
A number of free radical scavengers have been shown to protect the heart against DOX-
induced cardiotoxicity.  These include α-tocopherol, N-acetylcysteine, probucol, and 
dexrazoxane (Wang and others 1980; Herman and others 1985; Siveski-Iliskovic and others 
1995; Della and others 1996; Nazeyrollas and others 1999).  Dexrazoxane (Zinecard®), which is 
the most effective cardioprotective thus far in DOX-induced cardiotoxicity, prevents superoxide 
anion formation by associating with Fe2+ and by blocking the Fenton reaction (Malisza and 
Hasinoff 1996).  Unfortunately, all these compounds have pronounced clinical disadvantages.  
The protective effects were not consistently observed in DOX-induced cardiotoxicity (Breed and 
others 1980; Legha and others 1982; Wang and others 1980).  Probucol, a lipid-lowering 
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antioxidant, confers significant protection against DOX-induced cardiotoxicity (Siveski-Iliskovic 
and others 1995); however, concerns about its HDL-lowering property discourage its clinical 
application.  A cytoprotective drug, amifostine, has also been approved by the FDA to protect 
against DOX-induced cardiotoxicity, but it is less potent than dexrazoxane and does not prevent 
the mortality and weight loss caused by DOX in spontaneously hypertensive rats (Herman and 
others 1994).  Dexrazoxane, the only cardioprotective drug currently available clinically, only 
reduces 50% of DOX-related cardiac complications (Hasinoff 1998).  Moreover, it interferes 
with the anti-tumor activity of anthracycline antibiotics and potentiates DOX’s myelosuppression 
(Koning and others 1991; Sehested and others 1993). 
 
                
Fig. 2. Structures of melatonin and its analogs.  MEL, the pineal gland hormone; 6-OH MEL, the 
major metabolite of MEL; 8-M-PDOT, a MEL receptor agonist. 
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Another antioxidant, melatonin (MEL), the primary hormone of the pineal gland, has 
recently drawn attention (Fig. 2).  In addition to its circadian rhythm regulation activity, 
antioxidant properties of MEL are well documented (Reiter and others 2000).  It has been found 
that MEL acts as a powerful antioxidant and free radical scavenger of hydroxyl radicals (OH·), 
peroxyl radicals (ROO·), and superoxide anions (Reiter and others 1997).  Indeed, MEL has been 
shown to be twice as potent as Trolox in removing peroxyl radicals (Pieri and others 1994), and 
is 5 and 14 times more effective in scavenging hydroxyl radicals than glutathione and mannitol, 
respectively (Hardeland and others 1993).  The advantage of MEL is evident: unlike the confined 
distribution of vitamin C or vitamin E, MEL distributes readily in all subcellular compartments 
due to its water and lipid solubility.  As such, it passes through the cell membrane easily and 
enters cardiac cells to remove free radicals in situ.  Studies have shown that MEL protects the 
heart and brain against apoptosis and ischemia-reperfusion injury by removing free radicals 
(Kaneko and others 2000; Chen and others 2001; Sun and others 2002).  As a hormone, MEL 
may also exert its effects via MEL1a receptors in the heart.  Some MEL analogs like 6-
hydroxymelatonin (6-OH MEL) possess free radical scavenging capability (Dubocovich 1995), 
while others, such as 8-methoxy-2-propionamidotetralin (8-M-PDOT), bind to MEL receptors 
but have no antioxidant activities (Fig. 2).  To determine if MEL protects the heart against DOX-
induced cardiotoxicity and to explore the possible mechanisms involved, the effects of these 
compounds on mouse hearts were examined in the current study. 
 
Apoptosis and DOX-Induced Cardiotoxicity 
Until very recently, apoptosis was not known to be involved in DOX-induced 
cardiotoxicity (Arola and others 2000).  As such, the mechanisms involved in DOX-induced 
cardiac apoptosis and the role of apoptosis in DOX-induced cardiac injury are far from being 
understood.  Some studies indicate that apoptosis appears to contribute to the transition to heart 
failure and ischemia-reperfusion injury (Bialik and others 1997; MacLellan and Schneider 1997; 
Fadeel and others 1999).  An important aspect of the current study is the investigation of the 
mechanism of DOX-induced cardiac apoptosis. 
 
Characteristics and Pathways of Apoptosis 
Apoptosis is a process of programmed cell death that plays a critical role in normal 
embryologic development, homeostasis, tumor surveillance, function of the immune system, and 
organ regression in the senescence process (Kerr and others 1972; van den Hoff and others 
2000).  Diseases occur as a consequence of excessive apoptosis or failure of apoptosis.  In 
contrast to the classic necrosis resulting from an acute cellular injury, apoptosis is a genetically 
controlled process in which scattered single cells in a tissue actively participate in their own 
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demise.  Morphologically, apoptotic cells “shrink abruptly” and chromatin forms “dense 
crescent-shaped aggregates” under the nuclear membrane (Kerr and others 1972).  The plasma 
membrane integrity is initially preserved but subsequent convolution of the plasma membrane 
results in the formation of clusters of membrane-bound cellular organelles referred to as 
“apoptotic bodies” (Hengartner 2000; Saraste and Pulkki 2000).  Unlike necrosis, apoptotic 
bodies are rapidly devoured by tissue macrophages or neighboring viable cells, so there is no 
tissue inflammation.  Biochemically, apoptosis is initiated by activation of endogenous proteases 
that result in the cleavage of chromatin into oligonucleosome-size DNA fragments (Narula and 
others 1997; Hengartner 2000).  DNA fragmentation is now accepted as a biochemical hallmark 
of apoptosis, which can be recognized in multiple experimental techniques including DNA 
laddering, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL), 
and in situ oligo ligation (ISOL) (Allen and others 1997; Didenko and others 1998; Anversa 
2000; Stadelmann and Lassmann 2000).  Other significant changes in apoptotic cells include 
phosphatidylserine translocation in the plasma membrane, initiation of caspase cascade, and 
activation of poly ADP-ribose polymerase (PARP) (Thornberry and Lazebnik 1998; Wieder and 
others 2001). 
Previous studies indicate that apoptosis can be initiated in two principal pathways: 
intrinsic and extrinsic.  The intrinsic pathway emerges from mitochondria, whereas the extrinsic 
pathway is activated by the stimulation of death receptors, including Fas, tumor necrosis factor-α 
(TNF-α)-receptor, and TNF-α-related apoptosis-inducing ligand (TRAIL)-receptor (Ashkenazi 
and Dixit 1998; Green and Reed 1998).  While p53 and Bcl-2 family proteins play crucial roles 
in the intrinsic pathway, caspases relay apoptotic signals in both pathways.  Numerous studies 
have shown that Bax and mitochondria mediate apoptosis of cardiac myocytes stimulated by 
hypoxia and ischemia, though other pathways have also been reported (Long and others 1997; 
Leri, Liu, and others 1998; Borutaite and others 2001; Kubasiak and others 2002).  Activation of 
Bax was observed in apoptotic cardiac myocytes in human heart failure (Leri, Liu and others 
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1998).  It has been reported that p53 mediates apoptosis of cardiac myocytes stimulated with 
angiotensin II (Pierzchalski and others 1997; Leri, Claudio, and others 1998).  These studies 
strongly suggest that p53, Bax, and mitochondria play key roles in apoptosis of cardiac 
myocytes. 
Roles of p53 in Apoptosis 
The p53 tumor suppressor protein transmits signals arising from various forms of cellular 
stresses, including DNA damage, hypoxia, and nucleotide deprivation that induce cell cycle 
arrest and cell death (Yu and others 1997; Burns and el Deiry 1999; Regula and Kirshenbaum 
2001).  During cardiac failure, ischemia-reperfusion, and cardiac hypertrophy, p53 is heavily 
involved in cardiac myocyte apoptosis (Pierzchalski and others 1997; Leri, Liu, and others 1998; 
Fortuno and others 1999).  The transcription activation of p53 appears to be an important 
mechanism for exerting its biological effects, though it has been demonstrated to induce 
apoptosis in the absence of transactivation in some cell lines (el Deiry 1998; Gupta and others 
2001).  The pro-apoptotic Bcl-2 family member Bax, apoptotic ligand Fas, and others have been 
discovered as the downstream genes (Miyashita and Reed 1995).  The upstream events of p53 
activation are less clear, but the endpoint of the upstream pathway is that p53 protein levels are 
dramatically increased through either posttranslational modifications such as phosphorylation or 
transcriptional regulations (Huang and others 1999; Marchenko and others 2000; Xie and others 
2000).   
p53 protein is composed of a conserved N-terminal transactivation domain, a proline-rich 
domain, a sequence-specific DNA-binding domain, a tetramerization domain, and a basic C-
terminal tail (Fig. 3).  There is much evidence that the transcription activities of p53 protein can 
be activated by phosphorylation, in addition to the elevation of the protein levels (Chernov and 
others 1998).  In the past few years, considerable attention has been focused on the determination 
of phosphorylation sites within the N-terminal regulatory domain as well as the C-terminal 
domain.  Indeed, p53 has been shown to be phosphorylated on these serine residues by a number 
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of kinases, including MAPKs at Ser 15, 20, and 389 (Huang and others 1999; Shieh and others 
1999; She and others 2000), checkpoint kinase-2 at Ser 20 and 33 (Hirao and others 2000), and 
the DNA-dependent protein kinase at Ser 15 and Ser 37 (Shieh and others 1997; Smith and 
Jackson 1999). 
On the other hand, murine double minute clone 2 (MDM2) is a key negative player in the 
regulation of p53 activation and degradation, which has a unique relationship with p53 (Haupt 
and others 1997; Oren 1999).  MDM2 interacts with p53 at the N-terminal transactivation 
domain to inactivate the transcription activity and to induce ubiquitin-mediated proteolytic p53 
degradation; on the other hand, p53 binds to the specific promoter region of MDM2 gene and 
stimulates its transcription (Prives 1998; Momand and others 2000).  However, genotoxic or 
oxidative stresses induce modification of p53 and/or MDM2, particularly by phosphorylation, 
which blocks the interaction of MDM2 and p53, protecting p53 from degradation (Shieh and 
others 1997).  This leads to an accumulation and elevation of intracellular p53 protein levels. 
 
Fig. 3.  Domain Structure of p53 Human Protein.  Domains or regions are indicated as follows: 
activation and MDM2 binding domain (MDM2, TA), residues 1-60; growth suppression proline-
rich region (PXXP), residues 63-97; DNA-binding domain (DBD), residues 100-300; 
tetramerization domain (TD), residues 323-356; and basic C-terminal domain (BD), residues 
363-393.  Potential phosphorylation sites at N-terminal are Ser 6, 9, 15, 20, 33, and 37, which are 
phosphorylated by several kinases, such as MAPKs, DNA-dependent protein kinase, and 
checkpoint kinase II (Bulavin and others 1999; Harris 1996; Sanchez-Prieto and others 2000; 
Tominaga and others 1999).   
Increasing evidence indicates that p53 is involved in cardiac myocyte apoptosis (Ikeda 
and others 1999; Long and others 1997; Song and others 1999).  The expression of ventricular 
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p53 and its target gene Bax increased dramatically with a significant increase of myocyte 
apoptosis following rapid ventricular pacing in dogs (Leri, Liu, and others 1998).  On the other 
hand, mice can survive significantly longer after receiving heart transplantations from p53-
deficient mouse donors (Hu and others 2000).  Transfection of p53 into ventricular myocytes 
with the adenovirus induces apoptosis by initiating a mitochondria-dependent apoptotic pathway 
(Regula and Kirshenbaum 2001), and overexpression of Bcl-2 blocks p53-induced cardiac 
myocyte apoptosis (Kirshenbaum and de Moissac 1997).  These studies indicate that p53 plays 
critical roles in myocyte apoptosis in pathophysiological 
conditions. 
A chemical inhibitor of p53, pifithrin-α (PFT-α), 
has recently been found to deter p53-dependent apoptosis 
(Komarov and others 1999) (Fig. 4).  This effect is believed 
to be the result of PFT-α inhibiting the p53 transactivation 
activity and its downstream events such as activation of 
caspases and PARP (Lorenzo and others 2002).  Due to this 
action, PFT-α protects mice from lethal genotoxic stress associated with anti-cancer 
chemotherapy without promoting the formation of tumors (Komarov and others 1999).  In 
addition, PFT-α protects neurons against apoptosis induced by DNA-damaging agents, amyloid 
beta-peptide, and glutamate (Culmsee and others 2001).  The protection by PFT-α is correlated 
with declined p53 transcription activities and expression of Bax, the protection of mitochondrial 
dysfunction, and the inhibition of caspase activation.   
Fig. 4.  Structure of pifithrin-α 
While these data are interesting, few studies have been conducted on the roles of p53 in 
DOX-induced cardiac cell apoptosis and myocardial injury, and no study has been performed to 
examine the effects of PFT-α on DOX-induced cardiotoxicity.  One of the aims of the current 
study is designed to examine the role of p53 in DOX-induced cardiac cell apoptosis and the 
effects of PFT-α on DOX-induced myocardial damages. 
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Mitochondria and Bcl-2 Family Proteins 
Recent studies indicate that roles of mitochondria in apoptosis are expanding in many 
types of cells (Green and Reed 1998; Wang 2001).  Roles of mitochondria have been 
demonstrated in regard to two aspects: 1) Release of cytochrome c from mitochondria into the 
cytosol is one of three factors required for activation of downstream caspases in ischemic cardiac 
myocytes (Borutaite and others 2001).  2) Mitochondria inner membrane potential (∆ψm) is 
decreased during apoptosis (Susin and others 1998), and the loss of ∆ψm is mediated by the 
opening of a large multi-conductance channel, also known as the mitochondrial permeability 
transition pore (PTP).  The mechanism of PTP regulation remains a mystery and is currently 
being investigated in many laboratories, but its regulation certainly involves the Bcl-2 family 
proteins (Marzo and others 1998). 
Bcl-2 family proteins can be classified into anti-apoptotic and pro-apoptotic proteins 
according to their functions.  Pro-apoptotic proteins in this family including Bax, Bad, Bid, Bak, 
Bcl-x, Bik, and Bim, promote cell death, while anti-apoptotic proteins, including Bcl-2, BclxL, 
and Bcl-w, inhibit cell death (Adams and Cory 1998).  Bcl-2 proteins are located in the outer 
membrane of mitochondria or in the cytoplasm, and many other proteins in this family are 
associated with mitochondria as well (Reed and others 1998).  These proteins have been 
implicated in the regulation of two important aspects of mitochondria pathophysiology: (1) PTP 
opening; and (2) release of apoptotic proteins from the mitochondria into the cytosol.  Bcl-2 
family proteins directly participate in the regulation of PTP.  In one experiment, Bax was co-
purified with the PTP protein complex from the mitochondrial membrane, implying that Bax 
may be closely associated with the component of the complex.  When partially purified 
mitochondrial PTP protein complex was reconstituted in liposomes, they maintained some 
functions, including suppression of pore openings by recombinant Bcl-2, but not the mutant Bcl-
2 protein (Zamzami and others 2000; Zamzami and others 1998). 
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Bcl-2 family proteins also function as channels relating to the release of cytochrome c.  
Their three-dimensional structures indicate that Bcl-2 or Bax can form different sized pore or ion 
channels.  Generally, it is thought that cytoprotective proteins such as Bcl-2 tend to form small 
channels that assume a mostly closed conformation, whereas pro-apoptotic proteins such as Bax 
tend to form larger channels, assuming a mostly open conformation that prefers anions.  Other 
mechanisms may be involved in the antagonism of these proteins; for example, Bcl-2 may be 
able to prevent channel formation by Bax under some conditions (Korsmeyer 1999).  Regardless 
of the mechanism, the pro-apoptotic Bcl-2 family proteins induce the release of cytochrome c 
into the cytosol, initiating the activation of caspases in the presence of apoptotic protease 
activating factor-1 (Apaf-1) protein.  Although Bcl-2 family proteins are involved in cardiac 
myocyte apoptosis in a myriad of insults including ischemia and hypoxic stress, their 
involvement in DOX-induced cardiotoxicity remains to be investigated (Kubasiak and others 
2002; Kunisada and others 2002). 
 
Caspases and Apoptosis 
Caspases are a group of proteolytic enzymes that can specifically cleave the pro-enzymes 
into active enzymes (Thornberry and Lazebnik 1998).  Caspases can be classified into two 
functional groups: the initiator caspases and the executioner caspases.  Initiator caspases are 
responsible for processing and activating the executioner caspases including caspases-8 and -9.  
The executioner caspases such as caspases-3, -6, and -7, cleave a subset of proteins leading to 
characteristic morphological changes of apoptosis and DNA fragmentation.  The roles of 
caspases in apoptosis have been greatly delineated in the past few years (Yue and others 1998; 
Earnshaw and others 1999; Hacker 2000; Communal and others 2002).  In the intrinsic apoptotic 
pathway, the cytochrome c released from mitochondria functions as the caspase activator in the 
presence of Apaf-1.  In the extrinsic pathway, death receptors mediate the activation of caspase-
8, leading to the cleavage of executioner caspases such as caspase-3.  One of the downstream 
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targets of caspases is caspase-activated DNase (CAD), which cleaves DNA into nucleosomal 
DNA fragments. 
 Studies have shown that several caspases are activated in p53-mediated apoptosis in 
many cell lines.  Caspase-3 and caspase-9 are the major caspases activated in p53-mediated 
apoptosis.  For example, caspase-3-like activities were increased in p53-dependent apoptosis in 
HEK 293 cells treated with presenilins (Alves and others 2002), caspases-3 and -9 are activated 
in p53-dependent apoptosis in human colon cancer cells (Bartke and others 2001), and 
overexpression of p53 induces an increase of caspase-1 mRNA in MCF-7 cancer cells (Gupta 
and others 2001).  Interestingly, p53 induces apoptosis through the activation of caspases-3 and -
9 in human endothelial cells exposed to DOX (Lorenzo and others 2002).  Activation of caspase-
3 has been demonstrated in apoptosis occurring in human cardiomyopathy (Narula and others 
1999).  At any rate, different caspases are activated in apoptosis, dependent on the apoptotic 
pathways.  The current study is designed to determine which caspases are activated in DOX-
induced cardiac cell apoptosis. 
 
DOX Induces Cardiac Cell Apoptosis 
While few studies on the roles of cardiac cell apoptosis in DOX-induced cardiotoxicity 
have been conducted, several lines of evidence granted an impetus to explore whether DOX 
induces cardiac myocyte apoptosis and whether apoptosis plays a role in its cardiotoxicity.  First, 
superoxide anion or H2O2 induces cardiac myocyte apoptosis via mitochondrial pathways (von 
Harsdorf and others 1999).  DOX is known to generate superoxide anion in cardiac myocytes as 
well as in intact hearts; it may initiate apoptotic pathways through ROS generation.  Secondly, 
DOX causes mitochondrial morphological and functional damages (Lefrak and others 1973), 
leading to cardiac myocyte apoptosis by initiating mitochondria-dependent pathways.  
Mitochondria control the destination of cells and could mediate apoptosis in an intrinsic 
apoptotic pathway when cardiac myocytes are insulted by ROS (Bialik and others 1999; Cook 
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and others 1999).  Finally, the inhibitory activity of DOX on topoisomerase II leads to DNA 
damage, activating p53 to induce cell arrest or apoptosis.  In fact, DOX has been shown to 
induce acute cardiac myocyte apoptosis after DOX-treatment (Arola and others 2000; Nakamura 
and others 2000; Kalyanaraman and others 2002), although the possible involvement of 
apoptosis in DOX-induced cardiotoxicity remains to be determined. 
Multiple mechanisms could be involved in DOX-induced apoptosis.  DOX induces 
apoptosis through the ceramide pathway in cultured adult rat ventricular myocytes (Delpy and 
others 1999).  Others have reported that upregulation of Bax releases cytochrome c from 
mitochondria, activating caspases in DOX-induced cardiac myocyte apoptosis (Gamen and 
others 2000; Childs and others 2002).  Although p53 plays critical roles in apoptosis, its roles in 
DOX-induced cardiac apoptosis have not been studied.  To seek an effective approach to protect 
against DOX-induced cardiac cell apoptosis and cardiotoxicity, one major aim of the current 
study is to examine the involvement of a p53-dependent apoptotic pathway in DOX-induced 
cardiac cell apoptosis in an in vivo murine model.  In addition, the effects of PFT-α are 
investigated on DOX-induced cardiac cell apoptosis, ultrastructural alterations, and cardiac 
dysfunction. 
 
Rationale and Aims 
DOX-induced cardiotoxicity is an important issue, as the cardiotoxicity compromises 
DOX’s clinical application.  Despite extensive investigation, prevention of DOX-induced cardiac 
injury has achieved limited success.  Three approaches have been examined in previous studies:  
1) Development of new anti-tumor drugs to replace the current anthracycline antibiotics; A 
number of new anthracyclines have emerged over the past decades, but even the better-tolerated 
epirubicin and highly potent idarubicin have not shown much improvement of cardiotoxicity 
(Arcamone and others 1997).  2) Change of the drug format by wrapping DOX in the liposome; 
newly developed pegylated liposomal DOX has demonstrated a lower cardiotoxicity, but 
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mucosal and skin toxicity increase the intolerability of this drug (Alberts and Garcia 1997; 
Waterhouse and others 2001).  3) Administration of cardioprotective agents along with DOX; 
several antioxidants such as the iron-chelator dexrazoxane have been demonstrated to slow or 
attenuate DOX-cardiotoxicity.   Although dexrazoxane is the most effective in protecting against 
DOX-caused cardiac injury, its leukopenia, thrombocytopenia, and gastrointestinal toxicity when 
combined with DOX are of great concern (Von Hoff and others 1981; Kosty and others 2001).  
An ideal combination therapy would prevent DOX-induced cardiotoxicity without attenuating its 
anti-tumor activity or enhancing other side effects. 
The current study is designed to examine the effects of PFT-α and MEL on DOX-
induced cardiotoxicity.  It is hypothesized that DOX induces cardiac cell apoptosis via the 
generation of ROS and that apoptosis contributes to DOX’s cardiotoxicity.  ROS insult initiates 
the p53-dependent apoptotic pathway, in which pro-apoptotic protein Bax is upregulated and 
triggers the cytochrome c release from mitochondria to the cytoplasm.  In the presence of Apaf-
1, cytochrome c activates caspase cascades and eventually leads to DNA fragmentation.  It is 
further hypothesized that cardiac apoptosis plays critical roles in DOX-induced cardiotoxicity; 
therefore, antioxidant MEL or p53 inhibitor PFT-α would attenuate DOX-cardiotoxicity via the 
blockade of cardiac cell apoptosis (Fig. 5).  To test these hypotheses, an acute murine 
cardiotoxicity model was established as in a previous study (Weinstein and others 2000).  DOX-
induced cardiac cell apoptosis was detected by TUNEL or ISOL assay; and the apoptotic 
pathways were investigated with Western blot analysis, Ribonuclease protection assays (RPA), 
and gene SuperArray analyses.  The protective effects of PFT-α and MEL on DOX-induced 
cardiac dysfunction and myocardial damages were analyzed.  Finally, the anti-tumor activity of 
DOX in combination with PFT-α or MEL was analyzed in PC-3 prostate cancer cells. 
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Fig. 5.  Hypothesized mechanisms of DOX-induced apoptosis and cardiotoxicity.  CAD, 
caspase-activated DNase; ICAD, inhibitor of CAD; p38, a member of MAPKs; ERK1/2, 
extracellular signal-regulated protein kinase; MEK, a MAPK kinase; SAPK/JNK, stress-
activated protein kinase/c-Jun N-terminal kinase. 
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CHAPTER 2 
MATERIALS AND METHODS 
 
Animals and Drug Treatments 
 
Animals 
Male ICR mice were purchased from Harlan (Indianapolis, IN), and C57BL/6 MEL1a 
receptor-deficient mice were kind gifts of Dr. Steven M. Reppert (Harvard Medical School).  All 
mice were housed in climate-controlled facilities of the James H. Quillen College of Medicine, 
East Tennessee State University, accredited by the American Association for Laboratory Animal 
Care, and fed ad libitum.  Animal protocols were approved by the Committee of East Tennessee 
State University on Animal Care. 
 
Treatment of DOX, PFT-α, and MAPK inhibitors 
DOX·HCl was purchased from Pharmacia and Upjohn (Kalamazoo, MI) or Sigma (St. 
Louis, MO).  DOX solution (2 mg/ml) was injected (i.p.) at a single dose of 25 mg/kg for the 
survival study and 22.5 mg/kg for all other studies. 
Pifithrin-α (Calbiochem; San Diego, CA) was dissolved in 1.5% dimethyl sulfoxide 
(DMSO) and administered 30 min before and 2 h after DOX treatment, at a dose of 2.2 mg/kg 
(i.p.) each.  An equal volume of vehicle (1.5% DMSO in saline) was injected in control mice.  
MAPK inhibitors SB 203580, PD 98059, and SP 600125 (Calbiochem, San Diego, CA) 
were dissolved in distilled H2O, 1.5% DMSO, and a PPCES vehicle (30% PEG-400, 20% 
propylene glycol, 5% ethanol, 15% cremophor EL, and 30% normal saline), respectively.  These 
inhibitors were administered by i.p. injection 30 min prior to DOX treatment.  Control mice were 
injected with equivalent volumes of H2O, 1.5% DMSO, or PPCES vehicle accordingly. 
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Table 1  Summary of Inhibitors Used in the Study 
Inhibitor   Inhibited IC50  Effective dose    Solvent  References 
  Function 
SB 203580     p38  0.6 µM       5 mg/kg      H2O       (Zhao and others 2001) 
PD 98059     MEK 2 µM       2.5 mg/kg    1.5%DMSO      (Yue and others 2000) 
SP 600125     JNK  90 nM       15 mg/kg    PPCES      (Bennett and others 2001) 
Pifithrin-α     p53     -       2.2 mg/kg    1.5%DMSO      (Komarov and others 1999) 
 
Treatment of MEL and Its Analogs 
MEL and 6-OH MEL were purchased from Sigma (St. Louis, MO).  8-M-PDOT was a 
product of Tocris Cookson (Ballwin, MO).  MEL and 6-OH MEL were dissolved in 10% alcohol 
(5 mg/ml) and 10% DMSO (5 mg/ml), respectively.  They were delivered either by addition to 
the drinking H2O at a concentration of 10 mg/L or via osmotic pumps (Durect, Cupertino, CA) at 
a constant delivery rate of 2.5 µg/h (2 mg/kg/d), 24 h before DOX administration.  Control mice 
were administered equivalent volumes of vehicle via osmotic pumps. 
 
Analysis of Apoptosis 
 
DNA Laddering 
Heart tissue was digested in a lysis buffer containing 10 mM Tris-HCl (pH 8.0), 100 mM 
NaCl, 25 mM EDTA, 0.5% SDS, and 1 mg/ml proteinase K, at 37°C overnight.  The supernatant 
was extracted with phenol-chloroform-isoamyl alcohol (25:24:1) and genomic DNA was 
precipitated with isopropanol.  DNA was resuspended in Tris-EDTA (ethylenediaminetetra-
acetic acid) buffer and digested with RNase A (0.1 mg/ml) at 37 °C for 30 min.  DNA (20 µg) 
was electrophoresed in 1.4% agarose gel to observe multiples of 180 – 200 bp internucleosomal 
DNA fragmentation.  A 100 bp standard (New England Biolabs, Beverly, MA) was included as 
markers of DNA electrophoresis. 
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TUNEL Assay 
At the end of the experiments, a section of ventricular tissue was sliced, fixed in 4% 
buffered formaldehyde for 24 h, dehydrated, and embedded.  Myocardial sections (5 µm) were 
mounted on siliconized slides and dried at 37°C overnight.  To detect cardiac apoptosis, TUNEL 
assay was performed by a CardioTACS™ kit (Trevigen, Gathersburg, MD) according to 
manufacturer’s instructions.  Briefly, slides were deparaffinized in xylene and dehydrated with 
ethanol, followed by digestion with proteinase K.  The labeling reaction was conducted in the 
presence of TdT enzyme and dNTP at 37°C for 60 min.  The horseradish peroxidase (HRP) 
substrate TACS Blue was applied to visualize positive nuclei, and nuclear fast red was used to 
counterstain normal nuclei.  The percentage of TUNEL-positive cardiac cells was determined by 
counting 10 random fields per section under an Olympus BX40 microscope. 
 
ISOL Analysis 
In situ staining of DNA strand breaks in the serial section of each specimen was detected 
by the ApopTag ISOL kit using oligo A according to manufacturer’s instructions (Serologicals 
Corp., Norcross, GA) with some modifications.  The endogenous biotin was blocked with an 
Avidin/Biotin blocking kit (BioGenex, San Romon, CA).  As in the TUNEL assay, the 
peroxidase substrate TACS Blue was used to label positive nuclei, and nuclear fast red was used 
to counterstain normal nuclei.  The percentage of ISOL-positive cardiac cells was determined by 
counting 10 random fields/section. 
 
Cell Death ELISA 
Apoptosis was quantified in mouse hearts by a Cell Death Detection ELISA Plus kit 
(Roche Molecular Biochemicals, Indianapolis, IN).  Frozen heart tissue was pulverized in liquid 
nitrogen, and a portion of the heart powder was lysed in the buffer provided in the kit.  Samples 
were processed according to manufacturer’s instructions to determine the level of cytosolic 
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mono- and oligonucleosomes.  Protein content of the heart samples was determined by dye 
binding assay (Bio-Rad, Hercules, CA) to quantify the cytosolic histone-associated nucleosomes. 
 
Analysis of Gene Expression 
 
Isolation of Mouse Heart RNA 
Mice were sacrificed at different times after treatment.  Hearts were removed and rapidly 
frozen in liquid nitrogen until RNA isolation.  The heart tissue was pulverized in liquid nitrogen 
and homogenized in TRI REAGENT (Molecular Research Center, Inc., Columbus, OH) using a 
Brinkman polytron homogenizer.  After addition of 1-bromo-3-chloropropane, the homogenate 
was vortexed and centrifuged.  The supernatant was subsequently transferred into fresh tubes and 
RNA was precipitated with isopropanol.  Following centrifugation at 4°C, RNA was air-dried 
and resuspended in diethyl pyrocarbonate-treated H2O.  RNA was stored at -80°C until analysis.  
After spectrophotometric quantification at 260 nm, the integrity and loading of RNA were 
verified by agarose electrophoresis.  For SuperArray analysis, RNA was treated with DNase I (1 
unit/10 µg RNA), followed by re-extraction with phenol:chloroform:isoamyl alcohol (50:49:1). 
 
RPA Assay 
Apoptotic gene expression was analyzed with a RPA kit of multiple-probe templates, 
RiboQuant mouse apoptosis probe-2 (BD PharMingen Inc., San Diego, CA) and templates p53, 
Bax, BclxL, and MDM2 (Ambion, Inc., San Antonio, TX).  Briefly, 32P-labeled cRNA probes 
were synthesized from these templates using in vitro transcription according to manufacturer’s 
instructions.  The probes were either extracted with phenol-chloroform-isoamyl alcohol 
(25:24:1) or gel-purified, and then hybridized with 5 µg total RNA at 56°C overnight, followed 
by digestion with RNase A and T1.  Protected RNA fragments were extracted with phenol-
chloroform-isoamyl alcohol (25:24:1) and separated on a 5% polyacrylamide gel containing 8 M 
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urea.  Gels were dried and visualized by autoradiography.  Expression of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as an internal control.  Protected cRNA fragments 
were then quantified by densitometry with an AlphaImager system (Alpha Innotech Corp., San 
Leandro, CA) after evaluation of repeated exposures to obtain an adequate dynamic range of 
linear response.  
 
SuperArray Analysis 
The expression of apoptosis-related genes was profiled by a Mouse Apoptosis 
GEArrayTM Q kit (SuperArray Inc., Bethesda, MD) according to the manufacturer’s instructions.  
32P-cDNA probes were synthesized using in vitro reverse transcription from 10 µg of mouse 
heart RNA.  Probes were subsequently hybridized with gentle agitation at 60°C overnight with 
cDNA fragments of apoptosis-related genes immobilized on nylon membranes provided with the 
kit.  Membranes were washed several times and signals were visualized by autoradiography.  
Data were analyzed by quantifying the band density of genes as described above. 
 
Detection of Protein Levels 
 
Protein Extraction 
Mouse hearts were homogenized with a Polytron homogenizer in a buffer containing 20 
mM HEPES (pH 7.5), 150 mM NaCl, 3 mM EDTA, 3 mM EGTA, 2 mM DTT (dithiothreitol), 
1% NP-40, 0.1% SDS, 2 µg/ml leupeptin, 2 µg/ml pepstatin, and 1 mM phenylmethylsulfonyl 
fluoride.  Heart homogenates were incubated on ice for 30 min, followed by centrifugation at 
12,000 ×g for 20 min.  The supernatant was transferred, aliquoted, and stored at -80°C.  Protein 
concentrations were determined by a BCA protein assay using BSA as a standard (Pierce 
Chemical Co., Rockford, IL). 
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Western Blot Analysis 
The heart homogenate was resuspended in 2X sample buffer containing 125 mM Tris-
HCl (pH 6.8 at 25 °C), 3% SDS, 20% glycerol, 100 mM DTT and 0.03% bromophenol blue.  
Samples were subsequently heated at 95°C for 5 min.  Proteins were separated by 7.5% - 12% 
SDS-polyacrylamide gel and transferred onto a nitrocellulose membrane by using a Trans Blot 
SD Semi-Dry Electrophoretic Transfer Cell System (BioRad, Richmond, CA).  Membranes were 
blocked by gentle agitation in a TBS buffer (20 mM Tris-HCl, pH 7.6 at 25°C, 150 mM NaCl) 
containing 0.1% Tween-20 and 5% non-fat milk for 60 min at room temperature.  Blots were 
then incubated with specific antibodies (Table 2) at 4°C overnight, followed by incubation with 
corresponding secondary antibodies.  After washing 15 min 3 times, blots were detected with the 
ECLTM Western blot analysis detection reagent (Amersham Biosciences, Piscataway, NJ). 
Table 2  Antibodies Used in the Study 
Antibodies   Sources  
Bax Oncogene Res. Products (Cambridge, MA) 
p53, BclxL, MDM2 Santa Cruz Biotech (Santa Cruz, CA) 
p38, p-p38 (Thr180/Tyr182), ERK, p-ERK 
(Thr202/Tyr204), JNK, p-JNK (Thr183/Tyr185) 
p-p53 (Ser 6, 9, 15, 20, or 389) 
Cell Signaling Tech (Beverly, MA) 
actin   Sigma (St. Louis, MO) 
 
 
Electron Microscopy Analysis 
Ultrastructural changes of mouse hearts were analyzed as previously described (Liu and 
others 2002).  Briefly, hearts were fixed with 3% glutaraldehyde in 0.1 M sodium cacodylate 
buffer (pH 7.4) at room temperature for 4 h.  Heart tissues were rinsed with cold buffer, post-
fixed with 1% osmium tetroxide, dehydrated in a series of ethanol and propylene oxide, and 
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embedded in an Araldite/DDSA (dodecenyl succinic anhydride) mixture (Electron Microscopy 
Sciences, Fort Washington, PA).  Ultra-thin sections of the left ventricular wall were obtained 
with a Leica Ultracut UCT ultramicrotome (Leica Inc., Deerfield, IL) and placed on copper 
grids.  Samples were double stained with uranyl acetate and lead citrate and observed under a 
Philips TECNAI 10 electron microscope.  Two samples from each group were examined to 
detect the alterations of myocardial structures. 
 
Mouse Survival Study 
Mice were randomly assigned to eight groups (6 mice/group): control, DOX, MEL, DOX 
+ MEL, 6-OH MEL, DOX + 6-OH MEL, 8-M-PDOT, and DOX + 8-M-PDOT.  A single dose of 
DOX (25 mg/kg, i.p.) or an equivalent volume of saline was injected.  MEL, 6-OH MEL, or 8-
M-PDOT was administered in the drinking water (10 mg/L) 24 h prior to DOX injection and 
continuously until the mice were euthanized.  Mouse general condition was observed and body 
weight was recorded daily until termination of experiments.  Survived mice were euthanized by 
injection of 120 mg/kg pentobarbital on the 5th day following DOX injection. 
 
Analysis of Enzyme Activities 
 
Detection of Myocardial Caspase Activities 
Caspases-3 and -9 activities were measured by a colorimetric caspase activity assay kit 
(BIOMOL Research Laboratories, Inc., Plymouth Meeting, PA).  Heart tissue was homogenized 
in a lysis buffer (50 mM HEPES, pH 7.4, 0.1% CHAPS, 5 mM DTT, 0.1 mM EDTA, 0.1% NP-
40) followed by centrifugation.  The supernatant was stored at -70°C.  Caspase activity assays 
were initiated by incubating 75 µg of supernatant with specific colorimetric caspase-3 substrate 
(Ac-DEVD-pNA) or caspase-9 substrate (Ac-LEHD-pNA) in 100 µl of assay buffer in 96-well 
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microplates at 37°C for 2 h, and then read at 405 nm in a microplate reader.  Results were 
expressed as arbitrary unit (absorbance at 405 nm/mg protein). 
 
Measurement of Serum CPK Activities 
Total CPK activities of the mouse serum were assayed using a CPK test kit (Sigma, St 
Louis, MO) according to manufacturer’s instructions with modifications.  CPK activity was 
evaluated by the rate of the reaction, in which CPK catalyzes the transfer of a phosphate to ADP 
to form ATP leading to the reduction of NAD to NADH, a product that increases the absorbance 
at 340 nm (Szasz and others 1976).  One unit of CPK was defined as the reduction of 1 µmole 
NAD+ to NADH per min in a BIS-TRIS buffer (pH 6.9) at 25°C. 
 
Measurement of Serum MEL Concentrations 
 Serum was separated by centrifugation of blood at 4°C and stored at -20°C until use.  
Serum MEL level was measured using a radioimmunoassay kit (ALPCO Diagnostics, Windham, 
NH) according to manufacturer’s instructions.  Briefly, an equal volume of appropriately diluted 
serum was incubated with anti-MEL antibody and [125I]-MEL at 4°C overnight.  The solid phase 
secondary antibody was added and incubated for 15 min.  After centrifugation and aspiration of 
the supernatant, pellets were counted in a RIASTAR gamma counter (Packard Instrument Co., 
Meriden, CT). 
 
Cardiac Function Analysis 
 
In Vitro Cardiac Function Analysis 
 Isolated heart perfusion was performed using a modified Langendorff technique as 
previously described (Pouna and others 1996).  Mice were injected with sodium heparin (500 
units/kg, i.p.) 20 min prior to anesthetization with sodium pentobarbital (120 mg/kg, i.p.).  The 
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mouse chest was opened and the heart was rapidly removed and soaked in ice-cold Krebs-
Henseleit buffer (Appendix A).  Hearts were cannulated and perfused retrogradely with Krebs-
Henseleit buffer at 37°C.  A balloon was introduced into the left ventricle via the left auricle.  LV 
pressure and heart rate were monitored through a pressure transducer.  After a 30-min 
preliminary perfusion, LV pressure and heart rate (HR) were continuously recorded and analyzed 
with a computerized data acquisition and analysis system (DATAQ Instruments Inc., Akron, 
OH).  To better evaluate the cardiac function, LVDP (maximal LV pressure – minimal LV 
pressure) was calculated, and HR×LVDP was used to assess the left ventricular performance, as 
it reflects both chronotropic and inotropic activities of the heart.  Coronary effluent was collected 
and measured every 15 min. 
 
In Vivo Cardiac Function Analysis 
In vivo cardiac function was analyzed with an ultrasound-based technique as described 
previously (Geisterfer-Lowrance and others 1996; Kubota and others 1998).  Five days after 
DOX injection, mice were injected with heparin (500 units/kg, i.p.) and anesthetized with chloral 
hydrate (360 mg/kg, i.p.).  Mice were intubated with a 22-gauge soft catheter and ventilated with 
a rodent ventilator (Columbus Instruments, Columbus, OH) at a tidal volume of 0.3-0.5 ml and a 
respiratory rate of 120 breaths/min.  After a left thoracotomy, the pericardium was dissected to 
expose the heart.  A 26-gauge needle connected to a pressure transducer was introduced into the 
LV after an apical stab to measure the LV pressure.  Two pairs of 1-mm piezoelectric crystals 
were attached to the apex, aortic root, anterior, and posterior walls of the heart.  The inter-crystal 
distance, LV pressure, and electrocardiogram were recorded on a beat-to-beat basis.  Cardiac 
function parameters, including LVEDP, LV end-systolic pressure (LVESP), LVDP, HR×LVDP, 
first derivatives of LV pressure over time (±dP/dt), stroke volume (SV), and cardiac output (CO), 
were analyzed with a SonoSoft data acquisition and analysis system (SonoMetrics, London, 
Ontario, Canada).  At the end of the functional analysis, animals were sacrificed with an 
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overdose of sodium pentobarbital (120 mg/kg, i.p.).  Hearts were removed and perfused for 2 
min as Langendorff preparations to remove the remaining blood.  Portions of the mid-ventricle 
were fixed for morphological and apoptosis studies.  The remaining parts were stored in liquid 
nitrogen until use. 
 
Cell Culture and Treatments 
PC-3 prostate cancer cells were obtained from the American Type Culture Collection 
(Manassas, VA), and cultured in F12-K media supplemented with 10% fetal bovine serum.  
Approximately 3000 cells were plated into each well in a 96-well culture plate and allowed to 
attach overnight before they were subjected to further treatment. 
DOX was diluted with F-12K media and added to culture dishes at appropriate 
concentrations.  Experiments were terminated 4 d following treatment by washing with cold 
PBS.  To examine the effect of MEL or 6-OH MEL on DOX’s anti-tumor activity in PC-3 cells, 
MEL or 6-OH MEL was diluted with F-12K medium to appropriate concentrations.  Cells were 
pre-incubated with different concentrations of MEL (0.1 M-100 µM) or 6-OH MEL (0.01-10 
µM) for 1 h prior to the exposure to DOX.  Equivalent volumes of solvents (alcohol or DMSO) 
were added to the control cells.  To detect the effects of PFT-α on DOX’s anti-tumor activity, 
cells were treated with various concentrations of PFT-α (0.1-50 µM) or an equal volume of 
DMSO for 1 h and subsequently incubated with DOX. 
 
Measurement of Cell Density 
A sulforhodamine B colorimetric assay was used to measure the cell density as 
previously described (Skehan and others 1990).  Experiments were terminated by washing cells 
with warm PBS 4 d after treatment.  Cells were then fixed with a 10% ice-cold trichloroacetic 
acid.  A 0.4% sulforhodamine B solution was subsequently added and incubated for 20 min 
followed by washing with 1% acetic acid.  After overnight drying, the stain was dissolved in 10 
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mM Tris (pH 10.0) and read on a microplate reader at 490 nm.  Relative cell density was 
expressed as absorbance at 490 nm/well. 
 
Statistical Analysis 
All values except survival rate were expressed as means ± SEM.  Statistical differences 
between each pair of groups were determined by Chi-square test in the survival study.  In other 
studies, one-way ANOVA was used, followed by Tukey’s multiple comparison test if there were 
significant differences between the groups.  P < 0.05 was considered significantly different. 
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CHAPTER 3 
RESULTS 
 
DOX-Induced Cardiac Cell Apoptosis 
Cardiac cell apoptosis increased significantly following a single injection of DOX (22.5 
mg/kg, i.p.) in a time-dependent manner.  DNA laddering began to emerge in mouse hearts 3 d 
after DOX injection, and persisted until 5 d following treatment (Fig. 6).  This observation was 
confirmed by more quantitative approaches including TUNEL and ISOL analyses.  TUNEL 
analysis showed that positive myocardial nuclei increased 5-fold 3 days after DOX-treatment and 
6-fold 5 days after DOX-treatment (Fig. 7).  Similar results were achieved in the ISOL assay, a 
more specific DNA fragmentation staining procedure, in which 14.2% of cardiac cells showed 
ISOL-positive nuclei in hearts from mice 5 days after DOX-treatment, compared to 1.8% from 
control mice (Fig. 8).  Thus, DOX does induce cardiac cell apoptosis in the acute stages of its 
cardiotoxicity. 
 
Fig.  6.  DNA laddering formation in mouse hearts following DOX injection.  Mice were treated 
with DOX or an equal volume of saline and sacrificed at different time points.  Heart DNA was 
isolated and electrophoresed on 1.4% agarose gel.  Lanes 1 and 2, control; 3 and 4, DOX-treated 
3 d; 5, DOX-treated 5 d; 6, 100 base pair DNA marker. 
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Fig. 7.  DOX-induced cardiac cell apoptosis as analyzed by TUNEL.  Mice were treated with 
DOX (22.5 mg/kg, i.p.) or an equal volume of saline.  Hearts were removed at the indicated 
times and analyzed with TUNEL assay.  A, representative TUNEL staining showing positive 
nuclei.  a, control; b, DOX-treated 1 d; c, DOX-treated 3 d; d, DOX-treated 5 d.  B, percentage of 
TUNEL-positive nuclei.  aP < 0.05, vs. control and DOX-treated 1d, n = 6. 
 A B
 
Fig. 8.  ISOL assay showing DOX-induced apoptosis in mouse hearts.  DOX or an equal volume 
of saline was injected i.p. in mice.  Mice were sacrificed and hearts were removed 5 d after 
injection.  Ventricular sections were stained with an ISOL kit.  A, representative ISOL staining 
showing positive nuclei.  a, control; b, DOX-treated 5 d.  B, percentage of ISOL-positive nuclei 
in mouse hearts treated with saline or DOX for 5 d.  aP < 0.05, vs. CON, n = 6. 
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Mechanisms of DOX-Induced Apoptosis 
 To determine the signal pathways of DOX-induced cardiac apoptosis, mRNA levels and 
protein expression of apoptosis-related genes were examined.  It was found that p53 was 
phosphorylated at Ser 15 by p38 and ERK MAPKs, followed by the expression of p53-mediated 
downstream genes in mouse hearts after DOX injection.   
 
DOX Induces p53 Phosphorylation 
The p53 protein level was upregulated by DOX in mouse hearts as early as 4 h after 
DOX-treatment, despite a lack of upregulation of p53 mRNA levels (Fig. 9).  To delineate how 
DOX led to elevation of p53 protein, phosphorylation of p53 at Ser 6, 9, 15, 20, and 389 was 
analyzed by Western blot analysis, since posttranslational modification such as phosphorylation 
is the major regulatory mechanism resulting in the elevation of p53 protein (Lakin and Jackson 
1999; Lambert and others 1998; Gottlieb and others 2002).  Phosphorylated p53 (p-p53) at Ser 
15 was identified in mouse hearts as early as 1 h and peaked at 2 h after DOX treatment.  The 
level of p-p53 at Ser 20 was also increased, but the change was not significant (data not shown).  
On the other hand, phosphorylation of Ser 6, 9, 20, and 389 was not detected.  Phosphorylation 
of p53 at Ser 15 was followed by the elevation of p53 protein levels (Fig. 9).  This suggests that a 
relationship exists between the elevation of p53 protein and p-p53 at Ser 15. 
 
DOX (h)  0    0.5     1      2      4   16   24 
p-p53 Ser 15  
p53
actin
Fig. 9.  Phosphorylation of p53 
at Ser 15 and elevation of p53 
levels in DOX-treated mouse 
hearts.  Phosphorylation of p53 
at Ser 15 and p53 levels were 
detected by Western blot analysis with specific p-p53 at Ser 15 and p53 antibodies.  Actin was 
included as a loading control. 
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MAPKs Mediate the Phosphorylation of p53 
 To determine whether MAPKs play a role in the phosphorylation of p53, phosphorylation 
of MAPKs was measured in DOX-treated mouse hearts.  Phosphorylation of p38 began as early 
as 1 h after DOX treatment and declined after 2 h; phosphorylation of ERK occurred as early as 
half an hour in mouse hearts following DOX injection (Fig. 10).  In contrast, JNK MAPK was 
not phosphorylated in mouse hearts after DOX-treatment.  These results indicate that ERK and 
p38 are likely to mediate the phosphorylation of p53 at Ser 15. 
 DOX (h)          0    0.5     1     2      4     16  
- 38 KD 
 p-p38 
 
-38 KD p38 
- 44 KD 
 p-ERK1/2 - 42 KD 
- 44 KD 
 ERK1/2 - 42 KD 
- 54 KD 
 p-JNK 
- 46 KD 
- 54 KD 
 
JNK - 46 KD 
Fig. 10.  Phosphorylation of p38 and ERK1/2, but not JNK MAPK, in DOX-treated mouse 
hearts.  Mice were injected with DOX (22.5 mg/kg, i.p.) and sacrificed at designated times.  
Hearts were subjected to Western blot analysis using specific p-p38 (Thr180/Tyr182), p38, p-
ERK (Thr202/Tyr204), ERK, p-JNK (Thr183/Tyr185), and JNK antibodies. 
 
MAPK inhibitors were used to confirm roles of p38 and ERK MAPKs in mediating 
phosphorylation of p53.  Western blot analysis showed that SB 203580, a p38 inhibitor, partially 
inhibited the phosphorylation of p53 at Ser 15 but not p38 itself (Fig. 11A).  Also, the ERK 
inhibitor PD 98059 blocked the phosphorylation of ERK and partially inhibited the 
phosphorylation of p53 at Ser 15 at a dose of 2.5 mg/kg (Fig. 11B).  In contrast, SP 600125, a 
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JNK inhibitor, did not significantly inhibit the phosphorylation of p53 at Ser 15 at a dose of 15 
mg/kg (Fig. 11C).  These data indicate that p38 and ERK MAPKs mediate the phosphorylation 
of p53 at Ser 15. 
     CON DOX      DOX + SB         SB
p-p38       
p38  
p-p53 Ser 15  
p53    
A 
   CON             DOX      DOX + PD        PD
p-ERK  
ERK
 
p-p53 Ser 15  
p53   
B 
   CON           DOX      DOX + SP        SP
  
p-JNK 
JNK
 
p-p53 Ser 15 
 
p53  
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Fig. 11.  Effects of MAPK inhibitors on the phosphorylation of MAPKs and p53.  Mice were 
injected with DOX and/or MAPK inhibitors and sacrificed 2 h after DOX injection.  Hearts were 
subjected to Western blot analysis with specific antibodies against p-p53 (Ser 15), p53, p-p38 
(Thr180/Tyr182), p38, p-ERK (Thr202/Tyr204), ERK, p-JNK (Thr183/Tyr185), and JNK.  A, 
effects of p38 inhibitor SB 203580 (5 mg/kg) on the phosphorylation of p38 and p53.  B, effects 
of ERK inhibitor PD 98059 (2 mg/kg) on the phosphorylation of ERK and p53.  C, effects of 
JNK inhibitor SP 600125 (15 mg/kg) on the phosphorylation of JNK and p53.  SB, SB 203580l; 
PD, PD 98059; SP, SP 600125. 
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DOX Upregulates Expression of Apoptosis-Related Genes 
 RPA was used to evaluate changes of apoptosis-related genes in mouse hearts following 
DOX injection.  As shown in Fig. 12, RPA results indicate that the message levels of Bax, BclxL 
and MDM2 were induced as early as 12 h, peaked at 24 h after DOX-treatment, and declined at 
48 h.  Although these genes are p53 target genes, the mRNA level of p53 was not upregulated by 
DOX treatment. 
 
Bcl-w 
 
Bclx
Bak 
Bax 
GAPDH
 
Bcl-2 
p53Bad 
L32 
GAPDH MDM2 
DOX (h)  0   2    4   8  16  24 DOX (h)   0       12       24      48  
A B 
Fig. 12.  Upregulated mRNA levels of apoptosis-related genes in mouse hearts following DOX 
treatment.  Total heart RNA was extracted and subjected to RPA analysis as described in 
Materials and Methods.  The mRNA levels of apoptosis-related genes were determined by RPA 
with a RiboQuant Probe mAPO-2 (A), and p53 and MDM2 probes (B). 
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To confirm the above findings and to obtain a more complete profile of genes involved in 
DOX-induced apoptosis, mouse heart RNA was further examined by SuperArray analysis.  
Because most genes were upregulated within 24 h following DOX injection, gene expression 
levels were determined at this time point.  The pro-apoptotic genes Bax and TNFR2, as well as 
the anti-apoptotic gene BclxL, were upregulated at least 2-fold in mouse hearts (Fig. 13). 
 
    
 
A B 
Fig. 13.  SuperArray analysis showing gene expression of apoptosis-related proteins.  Mice were 
treated with DOX or an equal volume of saline and sacrificed 24 h later.  The expression of 
apoptosis-related genes was detected in mouse hearts by SuperArray assay.  A, representative 
gene expression analyzed by SuperArray; bottom panels represent shorter exposures of internal 
control gene β-actin.  B, densitometric analysis of gene expression.  aP < 0.05, CON vs. DOX, n 
= 3. 
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DOX Induces Protein Expression of Apoptosis-Related Genes 
Since DOX upregulated Bax, BclxL, and MDM2, all of which are p53 downstream 
genes, the protein levels of these genes were determined by Western blot analysis.  As shown in 
Fig. 14, protein levels of BclxL were increased as early as 2 h following DOX injection, while 
Bax and MDM2 were upregulated 2-3 fold in mouse hearts 24 h after DOX treatment.  These 
data are consistent with the results of RPA and SuperArray analysis.   
  DOX (h)      0  2  4 16   24 
   Bax - 19 KD 
     MDM2 - 90 KD 
     BclxL - 34 KD 
 actin - 42 KD 
 
Fig. 14.  DOX-induced protein expression of p53 target genes.  Mice were injected with DOX 
and sacrificed at indicated time points.  Heart protein was extracted and analyzed by Western 
blot analysis with specific antibodies against Bax, BclxL, MDM2, and actin as described in 
Materials and Methods. 
 
PFT-α Inhibits DOX-Induced Apoptosis and Cardiotoxicity 
 The above data (Fig. 9-14) indicate that p53-dependent apoptotic genes play a crucial role 
in DOX-induced apoptosis.  To test this possibility, the effects of the p53 inhibitor PFT-α on 
DOX-induced cardiac cell apoptosis, ultrastructural alterations, and cardiac dysfunction were 
determined. 
 
PFT-α Blocks DOX-Induced Cardiac Cell Apoptosis 
ISOL analysis was performed to determine whether PFT-α blocks DOX-induced cardiac 
cell apoptosis.  As shown in Fig. 15, DOX gave rise to a 5-fold increase of ISOL-positive nuclei 
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in cardiac cells at a single dose of 22.5 mg/kg; however, administration of PFT-α along with 
DOX almost abolished DOX-induced increase of ISOL-positive nuclei (DOX 13.2% vs. DOX + 
PFT-α 2.56%, P < 0.05, n = 6).  These data confirm that DOX induces cardiac cell apoptosis in a 
p53-dependent pathway and this apoptosis can be blocked by PFT-α. 
 
Fig. 15.  Effects of PFT-α on DOX-induced apoptosis in mouse hearts.  Mice were treated with 
DOX and/or PFT-α and sacrificed 5 days later.  Heart sections were stained with a modified 
ISOL kit.  aP < 0.05 DOX vs. CON, DOX + PFT-α, and PFT-α treated, n = 6. 
 
Effects of PFT-α on DOX-Induced Phosphorylation of p53  
 Western blot analysis showed that PFT-α had no significant effect on DOX-induced 
phosphorylation of p53 at Ser 15.  Thus, it did not inhibit the elevation of p53 protein levels in 
hearts of DOX-treated mice (Fig. 16 and 18). 
 
Fig. 16.  Effects of PFT-α on the phosphorylation of p53 at Ser 15 in DOX-treated mouse hearts.  
Mice were injected with DOX and/or PFT-α, and hearts were removed 2 h after treatment.  Heart 
protein was extracted and subjected to Western blot analysis with specific antibodies against p53 
and p-p53 at Ser 15. 
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PFT-α Inhibits DOX-Induced Expression of p53 Target Genes 
 RPA was employed to determine the effects of PFT-α on DOX-induced gene expression 
of p53 and its target genes.  As shown in Fig. 17, PFT-α blocked DOX-upregulated mRNA 
levels of Bax, BclxL, and MDM2 in mouse hearts 24 h following DOX treatment.  Neither DOX 
nor PFT-α had any effect on p53 gene expression in mouse hearts.  Along with the above data, 
this finding indicates that PFT-α targets the expression of p53 downstream genes in the DOX-
induced apoptotic pathway. 
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Fig. 17.  Inhibitory effects of PFT-α on the expression of p53 target genes in DOX-treated 
mouse hearts.  Mice were treated with DOX and/or PFT-α and were sacrificed 24 h later.  Total 
heart RNA was subjected to RPA analysis.  PFT-α inhibited the expression of BclxL, Bax (A), 
and MDM2, but not p53 (B).  Lane 1, CON; lane 2, DOX-treated, lane 3, DOX and PFT-α-
treated; lane 4, PFT-α-treated mice.  Intensity of protected bands was quantified by 
densitometric analysis (C).  aP < 0.05, DOX vs. CON, PFT-α, DOX + PFT-α, n = 3. 
 
PFT-α Inhibits Protein Expression of p53 Target Genes 
To confirm the above data, the effects of PFT-α on DOX-induced protein expression of 
p53 and its target genes in mouse hearts were analyzed by Western blot analysis.  While PFT-α 
significantly inhibited DOX-stimulated protein expression of Bax, BclxL, and MDM2 in mouse 
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hearts, it did not reduce DOX-upregulated protein levels of p53 (Fig. 18).  These results are 
consistent with the RPA data, in which PFT-α inhibited the gene expression of Bax, BclxL, and 
MDM2.  Since PFT-α did not affect the phosphorylation of p53, it did not block the increase in 
p53 protein level due to MDM2-mediated p53 degradation.  
 CON           DOX     DOX + PFT-α PFT-α
p53  
Bax  
 BclxL
   MDM2 
 actin 
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Fig. 18.  Effects of PFT-α on the protein expression of apoptosis-related genes.  Mice were 
sacrificed 24 h following DOX and/or PFT-α injection.  Protein expression of Bax, BclxL, and 
MDM2, and p53 were analyzed in mouse hearts by Western blot analysis. A, heart proteins were 
subjected to Western blot analysis with specific antibodies against p53, Bax, BclxL, MDM2, and 
actin.  B, densitometric analysis of protein expressions.  aP < 0.01, vs. CON; bP < 0.05, vs. DOX 
+ PFT-α; cP < 0.05, DOX + PFT-α vs. CON, n = 5. 
 
PFT-α Inhibits Caspase Activation 
 Activities of caspases-3 and -9 were measured in hearts from mice treated with DOX 
and/or PFT-α.  DOX induced 3-fold increases of caspases-3 and -9 activities in mouse 
myocardium.  PFT-α markedly inhibited DOX-induced activation of caspases-3 and -9 (Fig. 19).  
This indicates that caspases-3 and -9 play important roles in DOX-induced p53-dependent 
apoptosis, and that PFT-α inhibits apoptosis by blocking the activation of caspases-3 and -9. 
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 Fig. 19.  PFT-α blocked DOX-induced activation of caspases-3 and -9.  Mice were sacrificed 24 
h after DOX and/or PFT-α injection and hearts were removed for the measurement of caspases-3 
and -9 activities using a colorimetric caspase activity assay.  aP < 0.05 vs. other groups, n = 5. 
 
PFT-α Attenuates Myocardial Ultrastructural Alterations 
 Administration of DOX led to myocardial ultrastructural damage in the current study, a 
result that is consistent with previous reports (Lefrak and others 1973; Rosenoff and others 1975; 
Lambertenghi-Deliliers and others 1976).  Myocardial changes, characterized as cytoplasmic 
vacuolization, mitochondrial swelling, and dense bodies in cardiac mitochondria, were focally 
distributed in some myocytes but merged when groups of cells were affected.  More severe 
changes such as myofibrillar disorganization or loss were diffuse in some cardiac myocytes (Fig. 
20B).  Treatment with PFT-α dramatically suppressed the damage, particularly the degree of 
cytoplasmic vacuolization, mitochondrial swelling, and cristae disappearance.  Myofibrillar 
disorganization without myofibrillar loss was still present (Fig. 20C).  In contrast, no damage 
was found in hearts from PFT-α-treated mice (Fig. 20D).  These electron microscopic studies 
suggest that PFT-α protects mitochondrial function and membrane integrity of cardiac myocytes. 
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 Fig. 20.  PFT-α protected against DOX-induced myocardial ultrastructural alterations.  A, 
control; B, DOX; C, DOX + PFT-α; D, PFT-α.  DOX caused cytoplasmic vacuolization (v), 
mitochondrial swelling (m), and myofibril disarrangement and loss (f).  Administration of PFT-α 
dramatically attenuated DOX-induced myocardial damage.   
 
PFT-α Inhibits DOX-Induced Serum CPK Release 
 Since DOX causes disruption of the cardiac myocyte membrane, the release of 
intracellular CPK into the serum has been used to evaluate the existence and extent of cardiac 
myocyte injury (Lee and others 1991; DeAtley and others 1999).  The present study showed that 
mouse serum CPK was elevated 5 days after DOX treatment.  PFT-α partially inhibited the 
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DOX-induced increase of serum CPK (Fig. 21), implying that it protected the cardiac myocyte 
membrane integrity. 
 
Fig. 21.  Inhibition of DOX-induced elevation of serum CPK.  CPK activities were measured by 
a CPK test assay.  aP < 0.01, DOX vs. CON, DOX + PFT-α, PFT-α; bP, DOX + PFT-α vs. CON 
and PFT-α, n = 6.  
 
PFT-α Protects Against DOX-Induced Cardiac Dysfunction 
 In vivo cardiac function was analyzed in mice treated with DOX and/or PFT-α (Liu and 
others 2002).  Mice were randomly assigned to four groups: control, DOX, DOX + PFT-α, and 
PFT-α.  Heart weight and body weight were measured daily.  At the end of the experiments, the 
heart weight to body weight ratio (mg/g) was slightly increased in DOX-treated mice, compared 
to control mice 5 days after treatment (4.7 ± 0.13, vs. 4.4 ± 0.14, P > 0.05).  This change was not 
statistically significant and was primarily attributed to the progressive weight loss observed in 
DOX-treated mice.  Although DOX-treatment did not result in cardiac hypertrophy and 
dilatation within 5 days, it greatly suppressed cardiac function, as shown in Table 3.  DOX-
treatment results in a significant elevation of LVEDP and a suppression of LVDP, indicating a 
decline of LV contractility.  Due to the suppression of LV contractility, a reduction of SV and 
CO was observed in DOX-treated mice.  In contrast, mice administered with DOX and PFT-α 
showed marked improvement of cardiac function.  Compared to the control, PFT-α did not show 
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any effects on the cardiac function.  These data demonstrate that PFT-α improved LV 
contractility in DOX-injected mice. 
     Table 3.  Effects of PFT-α on DOX-Induced Cardiac Dysfunction 
              CON             DOX          DOX + PFT-α         PFT-α 
HR (beats/min)       461 ± 24          416 ± 29     457 ± 14         443 ±20 
LVDP (mmHg)      83.7 ± 4.1         64.4 ± 5.2a    81.4 ± 3.2        90.5 ± 4.0 
HR×LVDP   38,620 ± 2,924     25,780 ± 2,272a        37,320 ± 2,260    40,590 ± 3,382 
LVEDP (mmHg)      1.86 ± 0.9           8.4 ± 0.72a   1.02 ± 0.42        0.99 ± 0.4 
+dP/dt (mmHg/s)     3582 ± 217        1993 ± 299a          3297 ± 225       4291 ± 399 
-dP/dt (mmHg/s)     2581 ± 182        1493 ± 223a          2365 ± 321       3376 ± 182 
SV (µl)       9.73 ± 0.65         6.12 ± 0.49a   8.68 ± 0.59        9.70 ± 0.75 
CO (ml)                  4.29 ± 0.35         2.32 ± 0.23a   4.01 ± 0.35        4.83 ± 0.52 
 
Mice were injected with DOX and/or PFT-α.  Six out of nine DOX-treated mice survived.  In 
vivo cardiac function was measured 5 d after DOX injection by a SonoMetrics data acquisition 
and analysis system.  HR, heart rate; LVDP, left ventricular developed pressure; LVEDP, left 
ventricular end-diastolic pressure; ±dP/dt, first derivatives of left ventricular pressure; SV, stroke 
volume; CO, cardiac output.  aP < 0.01 vs. CON, DOX + PFT-α, and PFT-α. 
 
Effects of PFT-α on the Anti-Tumor Activities of DOX 
 To examine the effects of PFT-α on the anti-tumor activities of DOX, a p53-null prostate 
cancer cell line, PC-3, was treated with DOX.  The results indicate that DOX killed about 50% of 
PC-3 cells at a concentration of 80 nM (LC50), as determined by a sulforhodamine-stained cell 
density test (Fig. 22A).  Pre-incubation of cells with PFT-α at a concentration less than 10 µM 
did not have significant effects on the inhibition of PC-3 cells by DOX.  In contrast, PFT-α had 
toxicity at 50 µM and enhanced the cytotoxicity of DOX. 
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Fig. 22.  Effects of PFT-α on the anti-tumor potency of DOX.  Sulforhodamine B colorimetric 
assay was performed following treatment of PC-3 cells with DOX and/or PFT-α.  A, dose-effect 
study showing that the IC50 of DOX on PC-3 cells is 80 nM.  B, effects of PFT-α on the growth 
of PC-3 cells in the absence (open bars) or presence of DOX treatment (solid bars).  aP< 0.05 vs. 
treatments at other concentrations of PFT-α in the absence of DOX; bP < 0.05 vs. treatments at 
other concentrations of PFT-α in the presence of DOX, n = 6. 
 
MEL Protects the Heart against DOX-Induced Cardiotoxicity and Apoptosis 
 Previous studies indicate that DOX induces cardiotoxicity by the generation of ROS.  
This series of experiments were designed to investigate whether MEL, an antioxidant, protects 
against DOX-induced cardiotoxicity and cardiac cell apoptosis. 
 
MEL and 6-OH MEL Improve Survival of DOX-Treated Mice 
The general appearances of mice from each group (CON, DOX, MEL, DOX + MEL, 6-
OH MEL, DOX + 6-OH MEL, 8-M-PDOT, and DOX + 8-M-PDOT) were observed following 
DOX injection.  At the time of sacrifice, the surviving mice in the DOX, DOX + MEL, and DOX 
+ 6-OH MEL groups had common symptoms including weight loss, diarrhea, and ascites.  
However, these symptoms were much more severe in the DOX and DOX + 8-M-PDOT groups 
than in the other groups.  The survival rates of treated mice from each group are shown in Table 
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4.  While only 40-50% of the mice treated with DOX or DOX + 8-M-PDOT survived for 5 days, 
almost all animals that received MEL or 6-OH MEL survived for 5 days. 
Table 4  Effects of MEL, 6-OH MEL, and 8-M-PDOT  
on the Mortality of DOX-Treated Mice 
Treatment     Survival rate 
CON         8/8 
DOXa         8/20 
MEL         8/8 
DOX + MEL        20/20 
6-OH MEL        8/8 
DOX + 6-OH MEL        11/12 
8-M-PDOT        8/8 
DOX + 8-M-PDOTa       8/16 
 
Mice were injected with a single dose of DOX (25 mg/kg, i.p.) or an equivalent volume 
of saline.  The mice were given MEL, 6-OH MEL, or 8-M-PDOT in drinking water (10 mg/liter) 
24 h prior to injection and until sacrifice.  The number of surviving mice was observed for the 
next 5 d following DOX injection.  aP < 0.05 vs. other groups. 
 
MEL and 6-OH MEL Protect Cardiac Function in DOX-Perfused Mouse Hearts 
A dose-response study indicates that DOX significantly depressed cardiac function at 
concentrations higher than 1 µM (data not shown).  Perfusion of hearts with 5 µM DOX for 60 
min resulted in a 40% reduction of HR and a 30% suppression of dP/dt (Fig. 23, A and B).  
Perfusion of 5 µM DOX resulted in a 50% decrease of HR×LVDP as compared with the control 
group (Fig. 23C).  Exposure of mouse hearts to 1 µM MEL or 6-OH MEL 5 min prior to DOX 
treatment, followed by perfusion of these hearts with a buffer containing 5 µM DOX and 1 µM 
MEL, restored HR×LVDP to 85% of the basal level (Fig. 23C).  
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Fig. 23.  Effects of MEL, 6-OH MEL, and 8-M-PDOT 
on the cardiac function of DOX-perfused mouse hearts.  
Hearts were perfused as Langendorff preparations for 60 
min with Krebs-Henseleit buffer containing 5 µM DOX 
in the absence or presence of 1 µM MEL, 6-OH MEL, or 
8-M-PDOT as described in Materials and Methods.  
Functional parameters were expressed as the percentage 
of the baseline values measured after 30 min of stabilization.  A, heart rate; B, +dP/dt; C, 
HR×LVDP.  aP < 0.05, DOX vs. other groups except DOX + 8-MPDOT-treated; bP < 0.05, 
DOX + 8-M-PDOT vs. other groups except DOX-treated, n = 5. 
B
C
 
In addition, DOX caused a 45% decline of coronary flow rate (CFR) after 60 min of 
perfusion (Fig. 24A).  Treatment of the hearts with MEL or 6-OH MEL almost abolished DOX-
induced decline of CFR (Fig. 24B).  However, treatment of the heart with 1 µM 8-M-PDOT 
failed to restore cardiac function or coronary flow.  Because cardiac performance is closely 
related to the CFR, these results indicate that MEL or 6-OH MEL, but not 8-M-PDOT, improve 
the cardiac performance of DOX-treated mouse hearts by restoring coronary circulation. 
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Fig. 24.  Effects of MEL, 6-OH MEL, and 8-M-PDOT on DOX-induced reduction of coronary 
flow.  Hearts were perfused for 60 min with Krebs-Henseleit buffer containing 5 µM DOX in the 
absence or presence of 1 µM MEL, 6-OH MEL, or 8-M-PDOT.  Coronary perfusate was 
collected every 15 min and expressed as the percentage of basal levels.  A, DOX-perfusion 
resulted in a reduction of CFR; B, effects of MEL, 6-OH MEL, and 8-M-PDOT on the coronary 
flow rate of DOX-perfused hearts.  aP < 0.05, DOX vs. other groups except DOX + 8-M-PDOT-
treated, n = 5. 
 
Role of MEL1a Receptor in the Cardioprotective Effects of MEL 
To study if MEL acts on mouse hearts through its receptors, MEL1a receptor-deficient 
mouse hearts were perfused as described above.  The data show that MEL protects the cardiac 
function of both MEL1a receptor-deficient mice and wild-type mice (Fig. 25).  Pre-exposure of 
mouse hearts to 1 µM MEL 5 min prior to DOX perfusion, followed by perfusion of the heart 
with a buffer containing 5 µM DOX and 1 µM MEL, protected cardiac function and coronary 
flow of hearts from both wild-type and MEL1a receptor-deficient mice.  These results indicate 
that the protective effects of MEL are not mediated by MEL1a receptor. 
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 Fig. 25.  Effects of MEL on the cardiac function and coronary flow in DOX-perfused hearts of 
MEL1a receptor-deficient mice.  Mouse hearts were isolated and perfused as a Langendorff 
preparation.  Cardiac function (HR, +dP/dt, and HR×LVDP) and CFR were recorded and 
analyzed.  aP < 0.05, DOX vs. DOX + MEL in wild-type (WT) mice; bP < 0.05, DOX vs. DOX 
+ MEL in MEL1a receptor-deficient mice (KO). 
 
Plasma MEL Concentration in MEL-Administered Mice 
 The RIA results showed that plasma MEL concentration varies from 10.0 ng/ml to 22.3 
ng/ml with a mean concentration at 14.8 ± 1.5 ng/ml (0.06 µM) in osmotic pump-implanted 
mice.  On the other hand, the plasma MEL concentration was significantly lower in mice with 
MEL in the drinking water (4.7 ± 0.4 ng/ml (0.02 µM), P < 0.05).  Despite the difference, 
effective protection was obtained in mice administered MEL in their drinking water.  This 
indicates that the lower MEL concentration (4.7 ng/ml) in orally-administered mice, is sufficient 
to protect against DOX-cardiotoxicity.  Since the water consumption of each mouse (30 g) is 
about 5 ml/d, it was estimated that approximately 50 µg/d of MEL (or 1.67 mg/kg/d) would be 
adequate to protect animals against the acute toxicity of DOX. 
 
MEL and 6-OH MEL Protect In Vivo Cardiac Function 
Table 5 summarizes the hemodynamic indices (HR, LVEDP, LVESP, ±dP/dt, SV, and 
CO) of all surviving mice 5 days after treatment. DOX caused significant alterations of cardiac 
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performance at an acute dose of 22.5 mg/kg.  LVEDP was higher in the DOX group than in the 
CON group (P < 0.05), indicating that DOX impaired ventricular diastolic properties of the 
heart.  LVESP and ±dP/dt, 2 parameters of cardiac contractility, were significantly decreased in 
the DOX group.  There was no change in the LV end-diastolic dimensions among the groups, 
which indicates that acute DOX treatment does not induce cardiac dilatation.  Although HR in 
the DOX group was also not significantly lower than that in other groups, there was a 62% 
reduction in CO, which can be attributed to a significant decline in SV.  Administration of either 
MEL or 6-OH MEL dramatically improved all of the aforementioned cardiac function 
parameters.  These data indicate that MEL or 6-OH MEL improves DOX-impaired ventricular 
contractile function and compliance, which is consistent with the results from the in vitro mouse 
heart perfusion. 
Table 5  Effects of MEL and 6-OH MEL on the in vivo cardiac function in DOX-treated mice 
           HR            LVEDP         LVESP     +dP/dt  -dP/dt             SV          CO 
        (beats/min)     (mmHg)       (mmHg)       (mmHg/s)      (mmHg/s)        (µl)      (ml/min) 
CON         442±25        4.8±0.7       64.7±3.8    2638±127       2010±248      9.7±0.5    4.3±0.5 
DOX         388±30      10.7±2.1a      37.3±5.5a        904±156a        727±153a     4.1±0.4a   1.6±0.3a 
MEL         451±29        3.0±0.8       63.2±3.2    2664±120       1978±163      9.2±0.7    4.2±0.6 
DOX+MEL  415±29        4.3±0.8       60.2±1.2    1914±95         1629±143      7.4±0.8    3.2±0.4 
6-OH MEL   428±31        4.5±1.1       63.9±4.4       2384±334      1863±299       9.5±0.6    4.1±0.5 
DOX+         395±29        5.8±0.5       57.0±5.2       1774±208      1586±121       7.7±0.6    3.0±0.5 
6-OH MEL 
 
Mice were injected with DOX (22.5 mg/kg, i.p.) or saline.  MEL or 6-OH MEL was 
administered via a micro-osmotic pump at a constant delivery rate of 2.5 µg/h 24 h prior to DOX 
treatment and continuously until sacrifice.  Six out of 8 DOX-treated mice survived.  In vivo 
cardiac function was measured by the SonoMetrics system as described in Materials and 
Methods.  aP < 0.05 vs. all other groups, n = 6. 
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MEL and 6-OH MEL Protect Myocardial Ultrastructure 
Electron and light microscopic analyses of left ventricles were carried out in all six 
groups of mice.  No remarkable histopathological changes under the light microscope were 
observed between the control and DOX-treated heart when stained with hematoxylin and eosin.  
However, an electron microscopic study demonstrated extensive cardiac damage in DOX-treated 
mice characterized by mitochondrial degeneration and swelling, intracytoplasmic vacuolization, 
and focal myofilament disarray (Fig. 26 B and C).  Cellular damage was reduced dramatically by 
the administration of MEL or 6-OH MEL.  No myofilament disarray was identified in the hearts 
of DOX + MEL or DOX + 6-OH MEL mice, although a few intracytoplasmic vacuoles were 
observed in the hearts of these mice (Fig. 26 D and E).  MEL- and 6-OH MEL-treated mice 
showed normal ultrastructure of the heart.   The results indicate that MEL or 6-OH MEL is able 
to protect the integrity of subcellular structure of DOX-treated mouse hearts. 
 
 Fig. 26.  Representative electron 
micrographs showing 
morphological alterations of 
hearts from treated mice.  A) 
control; B) and C) DOX-treated; 
D) DOX + MEL-treated; E) 
DOX + 6-OH MEL-treated.  v, 
vacuolization; m, mitochondrial 
damages; f,  myofibril 
disarrangement and loss.   
 
 
 
 
 
69 
MEL and 6-OH MEL Attenuate DOX-Induced Elevation of Serum CPK 
While DOX-treatment resulted in a 3-fold increase of serum CPK activity as compared 
with the CON group (Fig. 27), administration of MEL or 6-OH MEL significantly decreased 
CPK release.  These results indicate that MEL or 6-OH MEL reduces DOX-induced necrosis in 
mouse hearts.  
 
Fig. 27.  MEL and 6-OH MEL protected DOX-induced CPK release.  Mouse serum CPK was 
measured as described in Materials and Methods.  aP < 0.05, DOX vs. all other groups, n = 6. 
 
MEL and 6-OH MEL Inhibit DOX-Induced Cardiac Cell Apoptosis 
 To explore the effects of MEL and 6-OH MEL on apoptosis, TUNEL and ISOL methods 
were used to identify apoptotic myocytes in DOX-treated mouse hearts.  Since the TUNEL assay 
may stain DNA fragments deriving from non-apoptotic processes, experiments were performed 
in the serial sections from each heart to determine myocyte apoptosis by the ISOL method.  The 
results showed that 15 ± 1.2% and 14 ± 1.0% of cardiac myocytes in DOX-treated mice were 
TUNEL- and ISOL-positive, respectively (Fig. 28).  Co-treatment of MEL or 6-OH MEL 
significantly attenuated apoptosis of cardiac myocytes in DOX-treated mice.  The effects of 
MEL and 6-OH MEL were further determined by a cell death ELISA assay.  As shown in Fig. 
29, whereas DOX-treated mouse hearts showed a fourfold increase of cytosolic nucleosomes 
compared with control mouse hearts, MEL or 6-OH MEL significantly inhibited DOX-induced 
DNA fragmentation. 
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Fig. 28.  Protective effects of MEL and 6-OH MEL on apoptosis in DOX-treated mouse hearts.  
Heart sections were stained by TUNEL (A) or ISOL (B).  Immunolabeled nuclei of cardiac cells 
were determined by random counting of 10 fields per section.  aP < 0.05, DOX vs. CON, DOX + 
MEL vs. MEL, or DOX + 6-OH MEL vs. 6-OH MEL, n = 6; bP < 0.05, DOX vs. DOX + MEL 
or DOX + 6-OH MEL; n = 6.  
  
 
Fig. 29.  Protective effects of MEL and 6-OH MEL on DNA fragmentation.   The cytosolic 
mono- and oligonucleosomes of mouse hearts were quantified by a Cell Death ELISAplus kit as 
described in Materials and Methods.  aP < 0.05, DOX vs. all other groups, n = 5. 
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Effects of MEL and 6-OH MEL on the Anti-Tumor Potency of DOX 
The effects of MEL and 6-OH MEL on the anti-tumor potency of DOX were performed 
in DOX-sensitive PC-3 cells.  Treatment of DOX at 80 nM results in the inhibition of growth of 
50% cells when cell density was measured with a sulforhodamine B colorimetric assay.  
Treatment of MEL (0.1-100 µM, which is far higher than the 0.06 µM in serum of MEL-
administered mice) or 6-OH MEL (0.01-10 µM) had no effect on the growth of PC-3 cells, nor 
the LC50 of DOX (Fig. 30).  Thus, MEL or 6-OH MEL did not change the potency of DOX in 
PC-3 cancer cells. 
  BA 
 
Fig. 30.  Effects of MEL and 6-OH MEL on the growth of PC-3 cells.  Cells were plated in 96-
well plates and allowed to attach overnight.  Various doses of MEL (0.1-100 µM) (A) or 6-OH 
MEL (0.01-10 µM) (B) was added 3 h before the application of DOX.  The number of surviving 
cells 4 d after addition of DOX (solid bar) or medium (open bar) was measured by 
sulforhodamine B colorimetric assay and was expressed as optical density per well.  aP < 0.05, 
DOX vs. CON; bP < 0.05, DOX vs. DOX + MEL or DOX + 6-OH MEL, n = 6. 
 
72 
CHAPTER 4 
DISCUSSION 
 
 In the current study, the protective effects of PFT-α and MEL against DOX-induced 
cardiac cell apoptosis and cardiotoxicity were investigated.  These studies indicate that PFT-α 
and MEL may protect the heart against DOX-induced cardiotoxicity in two different but related 
mechanisms: anti-apoptosis and antioxidant properties.  The major novel findings in the current 
study include: 1) DOX induces cardiac cell apoptosis mainly through the expression of p53-
dependent gene Bax and activation of caspases.  2) Activation of p53 by DOX is related to its 
phosphorylation at Ser 15 and is mediated by p38 and ERK1/2 MAPKs.  3) By blocking the 
expression of p53 downstream genes, PFT-α abolishes DOX-induced cardiac cell apoptosis and 
attenuates DOX-induced structural and functional damages.  4) MEL protects hearts against 
DOX-induced cardiotoxicity, at least partially by blocking cardiac cell apoptosis, which is 
related to its antioxidant activities. 
 
DOX Induces Apoptosis in a p53-Dependent Pathway 
 Identifying cellular events and signaling pathways of cardiac apoptosis are essential for 
understanding the mechanisms of DOX-induced cardiotoxicity, Because therapeutic approaches 
can be achieved through the inhibition of critical cellular events and blockade of signaling 
pathways.  The current study indicates that DOX induces cardiac cell apoptosis via a p53-
dependent pathway, in which p53 is regulated by phosphorylation at serine residues, followed by 
the elevation of p53 protein and expression of p53 target genes such as Bax, a gene whose 
product initiates cardiac cell apoptosis.  Revelation of these events in DOX-induced cardiac cell 
apoptosis will provide insights into the mechanisms, prevention, and treatment of DOX-induced 
cardiotoxicity. 
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DOX Induces Cardiac Cell Apoptosis 
The percentage of apoptotic cells was significantly increased in the early stage following 
DOX injection.  These results are consistent with a previous report that DOX induces cardiac cell 
apoptosis within a few days following DOX injection (Arola and others 2000).  Recently, 
numerous studies have indicated that apoptosis may be an important contributing factor to 
cardiovascular disease.  Apoptosis is involved in cardiac ischemia, and overexpression of Bcl-2 
attenuates ischemia-reperfusion injury through inhibition of cardiac apoptosis (Bialik and others 
1997; Chen and others 2001).  In human cardiomyopathy, mitochondria-mediated cardiac 
apoptosis is related to cardiac function (Narula and others 1999).  The current study indicates 
that DOX-induced cardiac apoptosis may play an important role in DOX-induced acute 
cardiotoxicity.  Previous histopathological studies revealed a striking reduction of cardiac cells in 
DOX-induced cardiomyopathy in patients (Lefrak and others 1973).  Loss of cardiac cells is one 
of the major features of DOX-induced cardiomyopathy and is an important cause of cardiac 
dilatation and failure.  Our studies indicate that cardiac apoptosis in DOX-treated mice may 
account for the cardiac cell loss. 
 The mechanism involved in DOX-induced cardiac apoptosis is important because the 
elucidation of apoptotic pathways may be helpful in drug discovery.  For instance, inhibitory 
apoptotic proteins (IAPs) are thought to be the potential targets of drug development (Reed 
2001).  However, the mechanisms involved in DOX-induced cardiac apoptosis have not been 
thoroughly explored.  The current study has explicated the possible pathways involved in DOX-
induced cardiac apoptosis.  As shown in previous studies, apoptosis can be mediated through 
death receptors such as Fas or TNFR, or initiated by mitochondrial dysfunction (Ashkenazi and 
Dixit 1998; Kroemer and Reed 2000).  Two important events triggering mitochondria-dependent 
apoptotic pathways include DNA damage and free-radical generation.  It is known that DOX can 
induce DNA damage as well as free radical generation (Davies and Doroshow 1986; Lee and 
others 1991; Bagchi and others 1995; Zhou, Palmeira, and others 2001).  Therefore, it is very 
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likely that DOX induces apoptosis in mitochondria-dependent pathways, which involve the 
upregulation of Bax and release of cytochrome c.  The current study has shown that the 
upregulation of Bax is dependent upon the phosphorylation of p53.  The results strongly suggest 
that DOX induces cardiac cell apoptosis in a p53-dependent pathway. 
 
Roles of p53 in DOX-Induced Apoptosis 
 Tumor suppressor gene p53 plays a pivotal role in cell differentiation and apoptosis 
(Burns and el Deiry 1999; Hirao and others 2000).  Activation of p53 initiates cell growth arrest 
or apoptosis in response to a variety of stress signals in order to eliminate damaged or potentially 
dangerous cells.  As such, p53 is extremely important in the surveillance of possible tumor cell 
formation in normal functioning.  Many chemotherapeutic drugs exert their anti-tumor actions by 
activating p53 to induce cancer cell apoptosis, and these include DNA damaging drugs, anti-
metabolites, microtubule-active drugs, and inhibitors of the proteosome (Blagosklonny 2002).  
Functionally deficient p53 has been observed in about 50% of cancers and heavily contributes to 
the multiple drug resistance observed in certain cancer therapies (Harris 1996).  Given all this, 
activation of p53 is a desirable goal during cancer chemotherapy. 
On the other hand, p53 is highly expressed in several normal tissues (such as 
hematopoietic tissues, intestinal epithelia, and testes) that are most commonly injured in cancer 
chemotherapy (Schwartz and others 1993; Komarova and others 1997).  The activation of p53 in 
normal tissues during chemo- or radio-therapy may cause apoptosis and cell injury.  For 
example, p53-dependent apoptosis in the intestinal epithelia could result in gastrointestinal side 
effects during cancer chemotherapy.  Indeed, overexpression of p53 facilitates cancer cell death, 
which is good to cancer chemotherapy; however, it increases normal cell death as well 
(Blagosklonny and el Deiry 1998).  Despite the relatively low expression of p53 in heart tissue, 
p53 has been reported to be responsible for cardiac myocyte apoptosis in various diseases (Long 
and others 1998; Ikeda and others 1999).  The mechanism of this apoptosis is believed to involve 
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the upregulation of pro-apoptotic genes by p53.  For instance, in cultured human endothelial 
cells, DOX induces apoptosis by a p53-dependent mechanism that involves triggering of 
mitochondrial cytochrome c release, activation of caspase-3, and downregulation of Bcl-2 
protein expression (Lorenzo and others 2002).   
The importance of p53 in DOX-induced cardiac cell apoptosis has been favored by the 
result that p53 inhibitor blocked the apoptosis by inhibiting the expression of p53 downstream 
genes, such as Bax, BclxL, and MDM2.  This result is consistent with a previous study which 
showed that p53 is a transcriptional activator of the Bax gene (Miyashita and Reed 1995), and it 
supports the notion that DOX-induced apoptosis involves upregulation of pro-apoptotic genes by 
p53.  Other studies indicate that the transcriptional activation of p53 may be an important 
mechanism in DOX-induced apoptosis.  In fact, p53 protein levels and transcriptional activities 
were upregulated in cells by genotoxic or hypoxic stresses (Sanchez-Prieto and others 2000; 
Koumenis and others 2001).  A recent research has shown that overexpression of a transcription 
factor, ATF3, inhibits cardiac myocyte apoptosis by downregulating p53 expression (Nobori and 
others 2002).  In contrast, the current study found that p53 protein levels are determined by 
phosphorylation of p53 at Ser 15.  Although the reasons for this discrepancy are unclear, it may 
be partly due to the different cell systems used in the two studies. 
 
Activation of p53  
 An accumulating body of evidence suggests that the stability and transcriptional activity 
of p53 is regulated by phosphorylation at multiple serine residues (Chernov and others 1998; 
Sakaguchi and others 1998; Huang and others 1999).  Phosphorylation at Ser 15 or Ser 20 
promotes the stability of p53 by blocking the interaction of p53 with its negative regulator 
MDM2, which plays a critical role in ubiquitin-dependent p53 degradation (Shieh and others 
1997).  In the current study, p53 was phosphorylated at Ser 15 in mouse hearts several hours 
after DOX injection.  This phosphorylation was followed by an elevation of p53 levels and 
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upregulation of downstream gene expression, indicating that p53 protein levels and activities can 
be upregulated via phosphorylation.  Although this relationship was not explored in the current 
study, one possible mechanism is the abolishment of the interaction between p53 and MDM2, as 
discussed above.  Alternatively, phosphorylation of p53 may increase the interaction of p53 with 
p300/CBP, an acetyl transferase that acetylates lysine residues located at the C-terminal of p53.  
This acetylation initiates the binding of p53 to specific gene promoters (Lambert and others 
1998).  In our unpublished experiments, it was found that p300/CBP was induced in mouse 
hearts after DOX injection.  Presumably, this result could be due to DOX-induced 
phosphorylation of p53, which upregulates p53 levels by facilitating the activity of p300/CPB.  
Regardless of whether p53 upregulation and activation occur via a decrease of p53-MDM2 
interaction, an increase of p53-p300/CPB interaction, or both, it is clear that phosphorylation of 
p53 enhances the transcriptional activity of p53 and results in the expression of downstream 
genes. 
It is worthy to mention that the regulation of p53 is complicated because it has multiple 
phosphorylation sites.  Ser 15 and Ser 20 are the most common phosphorylation sites when cells 
are attacked by genotoxic stresses (Huang and others 1999; Sanchez-Prieto and others 2000; She 
and others 2000).  The regulation of p53 is further complicated by the fact that phosphorylation 
is not the only mechanism of regulation; for instance, researchers have recently demonstrated 
that regulation of p53 involves the interaction of MDM2, Akt, and PTEN by either 
phosphorylation, translocation, or degradation (Gottlieb and others 2002; Mayo and Donner 
2002).  Despite the complexity of p53 regulation, it is certain from past studies and from the 
current study that at the very least, the activation and stability of p53 is regulated through 
phosphorylation at Ser 15 (Chernov and others 1998; She and others 2000).  Indeed, in this 
study, increased expression of Bax, BclxL, and MDM2 followed the phosphorylation and 
elevation of p53 in hearts from DOX-treated mice, implying that phosphorylation at Ser 15 
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initiates p53 transcriptional activation.  In summary, phosphorylation of p53 at Ser 15 plays a 
critical role in p53 activation in mouse hearts exposed to DOX. 
ERK1/2 and p38 MAPKs Mediate p53 Phosphorylation 
 Previous studies have demonstrated that members of the MAPK family play major roles 
in the phosphorylation and activation of p53 in response to ischemia/reperfusion and UV 
radiation (Bulavin and others 1999; Huang and others 1999; Keller and others 1999).  At least 
three subfamilies have been recognized in this family: p38, ERK1/2, and JNK MAPKs.  The 
current study shows that DOX induces the phosphorylation of MAPK p38 and ERK1/2 prior to 
phosphorylation of p53 at Ser 15 in mouse hearts.  The role of p38 and ERK1/2 MAPKs in the 
phosphorylation of p53 has been examined using specific inhibitors.  Both the p38 inhibitor SB 
203580 and the ERK1/2 inhibitor PD 98059 partially inhibited the phosphorylation of p53 at Ser 
15.  This was not true for SP 6000125, a JNK inhibitor, which indicates that only p38 and 
ERK1/2 MAPKs are involved in the phosphorylation and activation of p53 in DOX-treated 
mouse hearts.  
We here for the first time show that MAPKs mediate the phosphorylation of p53 in 
DOX-treated mouse hearts.  The conclusion that phosphorylation of p53 relies on DOX-induced 
phosphorylation of MAPKs is supported by a previous study indicating that another 
anthracycline antibiotic, daunorubicin, induces phosphorylation of MAPKs in cultured cardiac 
myocytes, although the phosphorylation of p53 was not examined in that study (Zhu and others 
1999).  One difference between the daunorubicin study and the current study is that daunorubicin 
was shown to phosphorylate all three members of the MAPK family, while DOX was shown to 
phosphorylate only p38 and ERK1/2, as discussed above.  It is not surprising that daunorubicin 
and DOX have different pathways in their actions on the heart, given that they are substantially 
different compounds. 
DOX probably induces the phosphorylation of MAPK through the generation of ROS, 
since a past study showed that DOX-initiated p38 phosphorylation was suppressed in cardiac 
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myocytes by the overexpression of antioxidant metallothionein (Kang and others 2000).  This 
indicates that ROS at least mediate DOX-induced phosphorylation of p38; more evidence is 
required to show that ROS also mediate the phosphorylation of ERK1/2 MAPK. 
Expression of p53 Downstream Genes 
 In this study, DOX enhanced expression of p53 downstream genes Bax, BclxL, and 
MDM2 in mouse hearts, transducing signals from p53 to the downstream events of cardiac 
apoptosis.  It is known that both Bax and BclxL are members of the Bcl-2 family proteins.  Bax 
is known to promote apoptosis, and it is involved in cardiac myocyte apoptosis of right ventricles 
from rats following pulmonary artery-banding (Liu and others 1998; Ikeda and others 1999).  In 
contrast, BclxL is an anti-apoptotic protein.  At first glance, it seems inconsistent that both a pro-
apoptotic gene (Bax) and an anti-apoptotic gene (BclxL) could be upregulated by p53.  However, 
it is known that the absolute level of expression of BclxL is not as important as changes in the 
Bax/BclxL ratio in determining apoptotic activity.  Furthermore, it has been reported that the 
loop domain of BclxL could be cleaved by caspases-1 and -3, and the C-terminal cleavage 
product is potently pro-apoptotic (Clem and others 1998).  Taking these into consideration, we 
think the upregulation of BclxL is not contradictory, its cleavage product may contribute to 
DOX-induced cardiac apoptosis, although it remains to be determined if BclxL is cleaved by 
activated caspases in DOX-treated mouse hearts.  
 MDM2 appears to have a very different function than Bax and BclxL.  Sequence analysis 
of the MDM2 promoter reveals the existence of a p53 DNA-binding consensus sequence, and 
p53 is known to augment MDM2 expression (Wu and others 1993).  As discussed previously, 
MDM2 is an important negative regulator of p53 that plays a major role in controlling the p53 
protein degradation rate (Haupt and others 1997; Honda and Yasuda 1999).  Specifically, MDM2 
binds to the N-terminal domain of p53 and acts as a ubiquitin ligase leading to p53 proteolysis by 
the 26S proteosome (Honda and Yasuda 1999).  As such, there is a negative feedback loop 
involved in the regulation of p53: p53 augments MDM2 expression, which in turn augments the 
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degradation of p53.  In this study, MDM2 was upregulated in the hearts of DOX-treated mice.  
Presumably, this would decrease p53 levels.  However, there was an increase in p53 levels due to 
the phosphorylation of p53 and subsequent upregulation of p53.  These seemingly contradictory 
findings might be due to the fact that phosphorylation of p53 at Ser 15 hinders its interaction 
with MDM2 (Shieh and others 1997), thus preventing MDM2 from augmenting p53 degradation.  
Further studies on this feedback loop may be helpful in finding approaches to block DOX-
induced cardiac cell apoptosis. 
 
PFT-α Protects the Heart against DOX-Cardiotoxicity Partly Due to Anti-Apoptosis 
 To confirm the hypothesis that DOX induces cardiac apoptosis in a p53-dependent 
pathway, the effects of PFT-α on DOX-induced cardiac cell apoptosis and cardiac injury were 
explored.  It was found that PFT-α almost abolished DOX-induced cardiac cell apoptosis.  PFT-
α achieved the blockade by inhibiting the p53 transcriptional activity and therefore the activation 
of caspases-3 and -9.  These effects of PFT-α may play crucial roles in its preserving myocardial 
structural integrity and protecting against DOX-induced cardiac dysfunction and release of CPK. 
 
Anti-Apoptosis of PFT-α and Protection against DOX-Induced Cardiotoxicity 
 As shown in previous and current studies, DOX treatment results in acute cardiac 
dysfunction in mice (Weinstein and others 2000; Pacher and others 2002).  Severe depression of 
left ventricular function has been shown to develop 5 days following DOX-treatment.  This 
depression manifests as reduced LVDP and elevation of LVEDP, thereby decreasing SV and 
CO, despite a lack of cardiac dilatation.  The acute cardiotoxicity and heart failure following 
DOX-administration in the mouse model observed in the current studies are consistent with 
clinical observations of DOX-induced cardiotoxicity.  In this study, administration of PFT-α 
along with DOX improved mouse cardiac function, with an accompanying dramatic reduction of 
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cardiac cell apoptosis.  Mice injected with DOX and PFT-α showed a relatively normal LVDP 
and LVEDP, indicating an improvement of cardiac contractility. 
The mechanisms involved in the protective effects of PFT-α are only partially 
understood.  It is likely that PFT-α improves cardiac function due to its inhibition of cardiac 
apoptosis.  Apoptosis has been shown to contribute to the development of cardiac failure in 
paced dogs (Leri, Liu, and others 1998); as such, inhibition of cardiac cell apoptosis would 
presumably protect cardiac function.  Indeed, inhibition of cardiac cell apoptosis by a p38 
inhibitor SB 203580 greatly improved the recovery of cardiac function in ischemia-reperfusion 
injury (Yue and others 2000).  Furthermore, overexpression of caspase-3 suppresses cardiac 
function recovery and exacerbates ischemia injury by enhancing cardiac cell apoptosis, 
indicating that protection of cardiac injury could be achieved by inhibiting cardiac myocyte 
apoptosis (Condorelli and others 2001).  In addition, activation of PARP, a substrate of caspases 
and a nuclear enzyme that mediates apoptosis and ROS damage by transferring ADP ribose units 
from NAD+ to nuclear proteins, promotes cardiac damage and development of heart failure in 
mice after DOX injection (Pacher and others 2002).  Hence, PFT-α attenuates DOX-induced 
cardiotoxicity at least partly due to its inhibitory effects on cardiac cell apoptosis. 
 
PFT-α Blocks DOX-Induced Gene Expression 
 PFT-α did not inhibit the elevation of p53 levels caused by DOX-induced 
phosphorylation of p53, but it blocked the p53-dependent expression of Bax, BclxL, and MDM2.  
These data indicate that PFT-α blocks transcriptional activities of p53.  It is only partly 
understood how PFT-α accomplishes this action.  In one study, PFT-α suppressed the 
translocation of p53 into nuclei and reduced the stability of nuclear p53, but it did not affect 
protein expression or sequence-specific DNA binding activity of p53 (Komarov and others 
1999).  In contrast, another study reported that PFT-α eliminates the elevation and DNA-binding 
activity of p53 protein in cultured human endothelial cells (Lorenzo and others 2002).  Given the 
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different cell system and dose of PFT-α in these studies, it is possible that the action of PFT-α 
on the phosphorylation and expression of p53 varies in different conditions and cell systems, 
thus explaining these contradictory results.  Regardless of which result is correct, all studies to 
date, including the current study, support the notion that PFT-α inhibits apoptosis through the 
blockade of a p53-dependent pathway. 
 
PFT-α Blocks DOX-Activated Caspases 
 In this study, caspases-3 and -9 were activated in DOX-treated mouse hearts.  This 
observation is consistent with previous studies in which activation of caspase-3 occurs following 
DOX treatment (Kumar and others 2001; Negoro and others 2001).  The upregulation of Bax 
seen in this study indicates that cytochrome c may be released from mitochondria to initiate the 
activation of caspase-9, which cleaves the pro-caspase-3 into active caspase-3.  Indeed, DOX has 
been shown to induce cytochrome c release in cultured cardiac myocytes and animal hearts 
(Wang and others 2001; Childs and others 2002).   
Several studies suggest that upregulation of Bax and activation of caspase-3 are critical 
events in DOX-induced cardiac cell apoptosis.  For example, inhibition of Bax by 
overexpression of BclxL has been shown to abolish DOX-induced caspase-3 upregulation 
(Kunisada and others 2002).  Furthermore, overexpression of caspase-3 is sufficient to induce 
cardiac myocyte apoptosis (Wu and others 2000).  Given all this, inhibition of Bax or caspase-3 
would likely be adequate to block DOX-induced cardiac cell apoptosis.  In the current study, the 
finding that treatment of mice with PFT-α dramatically reduces expression of Bax and activities 
of caspases-3 and -9 indicates that PFT-α may be effective in blocking DOX-induced 
cardiotoxicity by blocking DOX-induced apoptosis.    
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PFT-α Protects against DOX-Induced Myocardial Damage  
 DOX is known to cause ultrastructural changes of myocytes including cytoplasmic 
vacuolization, mitochondrial damage, and myofibrillar loss (Lefrak and others 1973; Rosenoff 
and others 1975; Billingham and others 1978).  Because DOX triggers membrane peroxidation 
and disruption, release of CPK from myocytes is a marker of myocardial damage, which can 
therefore be quantified by measuring the CPK levels in the blood or culture medium (DeAtley 
and others 1999).  In the current study, ultrastructural changes were observed shortly after DOX 
treatment in mice at a high dose of 22.5 mg/kg.  Pre-treatment of mice with PFT-α significantly 
attenuated both these myocardial ultrastructural changes as well as the release of CPK.  These 
experiments indicate that PFT-α inhibits DOX-induced myocardial damage. 
It is not clear how PFT-α protects myocardial lesions in DOX-administered mice.  
However, the cardioprotection is possibly related to the protection of mitochondrial function.  
Mitochondria play key roles in myocardial damage, as they control cell destination by 
dominating energy metabolism and by initiating apoptosis.  There is much evidence that DOX 
induces mitochondrial dysfunction.  First, mitochondrial swelling and cristae disappearance have 
been observed in hearts from animals injected with DOX (Ferrans 1978).  Second, DOX causes 
loss of mitochondrial membrane potential and activates caspases-3 and -9 in Jurkat cells (Gamen 
and others 2000).  Third, treatment of isolated rat heart mitochondria with DOX leads to 
cytochrome c release, indicating that mitochondrial membrane function is damaged after 
exposure to DOX (Green and Leeuwenburgh 2002).  Finally, cytochrome c release and cardiac 
myocyte apoptosis have been observed in animals and cultured cardiac myocytes exposed to 
DOX (Wang and others 2001; Childs and others 2002).  In this study, PFT-α blocked Bax 
protein expression and activation of caspase-3.  In addition, PFT-α blocks DOX-induced 
activation of caspase-12 (data not shown), which in turn activates caspase-9 (Morishima and 
others 2002).  These results suggest that PFT-α inhibits DOX-induced Bax expression to protect 
mitochondria function, thereby preventing the activation of caspases. 
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Effects of PFT-α on the Anti-Tumor Potency of DOX 
 PC-3 is a DOX-sensitive prostate carcinoma cell line widely used to investigate the 
cytotoxic effects of various anti-cancer drugs, including DOX and other anthracycline 
derivatives (Carroll and others 1993; Polin and others 1997; Teicher and others 1997).  DOX 
inhibits PC-3 cell growth and proliferation via a p53-independent apoptotic pathway; indeed, 
these cells lack expression of functional p53 (Wu and others 2002).  In this study, PFT-α did not 
show any negative effects on the anti-tumor activities of DOX; in fact, it actually enhanced this 
activity at higher concentrations.  Such an enhancing activity would be an especially valuable 
advantage in a combination PFT-α and DOX treatment in cancer chemotherapy. 
 Since p53 plays key roles in the checkpoint of cell growth and replication, the inhibition 
of p53 by PFT-α has raised concerns about its potential influence on normal cell life.  A study 
has recently demonstrated that PFT-α decreases genetic stability in combination with another 
anti-neoplastic drug etoposide (Bassi and others 2002).  If this finding is confirmed, secondary 
malignancies could emerge during long-term combination PFT-α and DOX treatment.  Clearly, 
further research is required before any application of PFT-α can be initiated.  Such research 
would be extremely justified, as this study suggests that PFT-α could be developed to prevent 
cardiotoxicity without decreasing the potency of DOX in p53-mutant cancer patients. 
 
MEL Protects the Heart Against DOX-Induced Cardiotoxicity 
Another aim of the current study was to investigate the protective effects of MEL on 
DOX-induced cardiotoxicity and apoptosis.  In the study, MEL dramatically improved survival 
rates in mice treated with an acute high dose of DOX.  Moreover, MEL was able to attenuate the 
acute effects of DOX-induced cardiac dysfunction and myocardial damages in mouse hearts.  
The cardioprotective effect of MEL could be attributed in part to the suppression of DOX-
induced apoptosis of myocytes. 
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  Antioxidant Activities of MEL and Its Protection of Cardiac Function 
 Many studies have shown that MEL has free radical scavenging capability (Beyer and 
others 1998; Antunes and others 1999; Karbownik and Reiter 2000).  For instance, MEL can 
protect rat hearts against ischemia-reperfusion injury by scavenging hydroxyl radicals (Kaneko 
and others 2000).  Since MEL has a relatively short half-life, its metabolite 6-OH MEL is of 
great interest.  Past studies have examined the antioxidant activities of 6-OH MEL and a MEL 
analog, 8-M-PDOT.  It was found that 6-OH MEL is almost as potent as MEL, but that 8-M-
PDOT does not show any free radical scavenging ability (Liu and others 2002). 
MEL or 6-OH MEL protects against DOX-induced cardiac dysfunction in both in vitro 
and in vivo studies.  MEL or 6-OH MEL reversed DOX-induced functional suppression 
(including impaired contractility and diastolic properties), decreased coronary flow rate, and 
reduced HR in perfused mouse hearts.  The in vivo study revealed a pronounced elevation of 
LVEDP, decline of LVESP, and a consequent reduction of SV and CO in DOX-administered 
mice, despite the lack of cardiac hypertrophy and dilatation.  However, administration of MEL or 
6-OH MEL reversed DOX-induced depressions of SV, LVESP, and LVEDP by improving 
cardiac contractility. 
Previous work suggests that MEL’s cardioprotective effect can be attributed mainly to its 
antioxidant activity.  For instance, MEL has recently been shown to attenuate DOX-induced 
changes in both the GSH/GSSG ratio and lipid peroxidation in the brain, heart, lung, and kidney 
(Agapito and others 2001).  The present study expands on this work by providing more evidence 
for the importance of MEL’s antioxidant activity in its cardioprotective effect.  Specifically, 
administration of MEL or 6-OH MEL dramatically improved survival rates of DOX-treated 
mice; in contrast, administration of 8-M-PDOT did not show any effects.  Furthermore, it was 
demonstrated that MEL protects MEL1a receptor-deficient mice as well as their wild-type 
littermates against DOX-induced cardiotoxicity, excluding a significant role of the MEL1a 
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receptor in the actions of MEL.  Taking all these observations into consideration, the improved 
survival rates for animals treated with MEL or 6-OH MEL is primarily due to their antioxidant 
activities, not to their receptor-mediated activities. 
MEL or 6-OH MEL, but not 8-M-PDOT, reversed DOX-induced impairments of cardiac 
function in the perfused mouse heart.  DOX caused suppression of cardiac contractility and 
reduction of HR, results that have been repeatedly observed in isolated mouse heart perfusion 
(Chen and others 1987; Ganey and others 1991; Platel and others 1999).  The cardiac 
contractility injury has convincingly been shown to be related to free radical generation 
(Rajagopalan and others 1988).  In contrast, the mechanism of HR reduction remains less clear 
due to the unavailability of effective research methods.  One possibility is that DOX or DOX-
induced ROS formation causes disturbances in calcium homeostasis, leading to a reduction of 
heart rate due to a decrease in intracellular calcium that reduces excitability of pacemaker cells in 
the sinoatrial node and other cells in the cardiac conduction system.  This speculation was partly 
supported by the fact that DOX prolonged the duration of ventricular action potentials in isolated 
papillary muscle fibers by generating free radicals, as well as by the fact that the antioxidant 
vitamin E protects against this effect (Venditti and others 1998).  It is very likely that MEL and 
6-OH MEL reversed the reduction of heart rate in DOX-perfused mouse hearts via their 
antioxidant activities in this study.  
The reduction of coronary flow seen in DOX-treated mice may have resulted from DOX-
induced coronary vascular constriction.  DOX-generated superoxide radicals are able to form 
peroxynitrite in the presence of NO (Weinstein and others 2000), possibly leading to a decrease 
in endogenous NO and a subsequent constriction of coronary vessels.  This hypothesis is 
supported by the fact that an increase in coronary resistance has been observed in DOX-perfused 
rat hearts (Pelikan and others 1986).  If this hypothesis is indeed correct, then it is possible that 
the reversal of DOX-induced reduction of coronary flow by MEL and 6-OH MEL was due to 
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their ability to scavenge superoxide radicals.   Clearly, however, more studies would need to be 
performed to definitively establish such a conclusion.  
 
In Vivo vs. In Vitro Cardiac Function 
 The cardiac function studies were designed to measure hemodynamic changes in 
response to DOX administration as exemplified in the in vitro studies, and to determine the 
magnitude of DOX-induced cardiotoxicity after 5 days.  In the in vitro studies, cardiac 
dysfunction occurs in the absence of structural changes because DOX-induced superoxide anions 
are known to compromise mitochondrial function by inhibiting mitochondrial complex I activity 
as well as by disrupting the mitochondrial permeability transition pore (Yen and others 1999).  
The ensuing increase in apoptosis occurred after 48 h of DOX administration (result not shown).  
Five days after DOX administration, there was no cardiac hypertrophy or cardiac dilatation in 
DOX-treated hearts.  Therefore, the model used in this study is different from DOX-induced 
chronic cardiomyopathy in patients or experimental animals.   
 In the in vivo study, there were no remarkable histopathological lesions observed under 
the light microscope, an observation that was in agreement with a previous study in mice 
overexpressing MnSOD (Yen and others 1996).  However, apoptosis and ultrastructural damage 
of the mitochondria and myofibrils was very evident, and these changes are certainly a major 
factor in cardiac dysfunction. 
 
MEL Protects Against DOX-Induced Myocardial Lesions 
As described above, DOX induces myocardial damage, characterized by cytoplasmic 
vacuolization, mitochondrial swelling, and myofibril disarrangement, which is consistent with 
results observed in previous studies (Rosenoff and others 1975; Billingham and others 1978; 
Bellini and Solcia 1985).  DOX-induced mitochondrial injury is especially important to the heart 
because it would presumably have disastrous effects on cardiac myocytes; indeed, because 
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mitochondria are the primary sites of energy production, mitochondrial injury would severely 
compromise the contractile function of cardiac myocytes by restricting energy metabolism.  It 
has been previously established that DOX induces mitochondrial injury in the heart through 
generation of superoxide anions, which can be attenuated by overexpression of MnSOD in mice 
(Yen and others 1996).  This suggests that the improvement of cardiac function by MEL or 6-OH 
MEL in the present study can be attributed at least in part to the preservation of the subcellular 
integrity of cardiac myocytes.  
 
Effects of MEL and 6-OH MEL on DOX-Induced Apoptosis and Necrosis 
 The current studies have shown that MEL and 6-OH MEL dramatically attenuated DOX-
induced cardiac apoptosis.  Previous studies have reported that cardiac injury induced by 
anthracycline antibiotics involves apoptosis of cardiac myocytes, but the mechanisms involved 
remain to be elucidated (Kumar and others 1999; Zhu and others 1999; Arola and others 2000; 
Wang and others 2001).  The most probable mechanism of DOX-induced apoptosis involves the 
production of DOX-generated ROS.  Several groups have shown that DOX induces apoptosis in 
both cultured cardiac myocytes and hearts from treated animals (Maulik and others 1998; Kumar 
and others 1999; Nakamura and others 2000).  Moreover, DOX-induced apoptosis in cultured 
cardiac myocytes and endothelial cells was inhibited by free radical scavengers, implying that 
free radicals at least partly contribute to DOX-induced cardiac apoptosis (Kotamraju and others 
2000).  These studies suggest that DOX induces apoptosis through free radical production, and 
that apoptosis contributes to DOX-induced cardiotoxicity.  This may explain how MEL or 6-OH 
MEL reduces cardiac apoptosis in DOX-injected mice; their antioxidant activities apparently 
play important roles.   
Due to their free radical scavenging capability, MEL or 6-OH MEL diminished serum 
CPK elevation in DOX-treated mice.  As shown in previous studies, DOX induces lipid 
peroxidation through generation of free radicals, leading to release of CPK from myocytes (Lee 
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and others 1991; Luo and others 1997; DeAtley and others 1999).  The results of the current 
study indicate that MEL or 6-OH MEL may protect myocytes against membrane damage 
induced by DOX, thereby protecting their structure and function. 
  
Effects of MEL or 6-OH MEL on the Potency of DOX 
PC-3 cells have been used to observe the effects of MEL or 6-OH MEL on anti-tumor 
activities of anthracycline antibiotics like DOX, as discussed above.  In this study, incubation of 
PC-3 cells with either MEL or 6-OH MEL did not have any antagonistic effect on the cytotoxic 
activities of DOX.  These results are inconsistent with previous reports that MEL can enhance 
anti-tumor activities of DOX in certain tumor-bearing mice and that MEL can increase the 
efficacy of other cancer chemotherapy in cancer patients (Lissoni and others 1999; Wahab and 
others 2000).  This discrepancy may be attributed to differences in experimental models and 
conditions, or they may be due to a difference in the response of different tumors to MEL.  
Although MEL did enhance the anti-neoplastic effects of DOX in the current study, the results 
clearly show that MEL or 6-OH MEL does not interfere with DOX’s anti-tumor activity.  
 
Future Directions 
 This study has shown that DOX induces acute cardiotoxicity at a single dose injection.  
p53-dependent cardiac cell apoptosis plays an important role in DOX-induced cardiotoxicity.  
Both the p53 inhibitor PFT-α and the antioxidant MEL can attenuate DOX-induced 
cardiotoxicity, partially because of their inhibition of DOX-induced cardiac apoptosis.   
However, all of these results used an acute cardiotoxicity model.  The effects of PFT-α 
and MEL on DOX-induced chronic cardiomyopathy should be further investigated.  In addition, 
the mechanism involved in PFT-α and MEL should be further explored in a cultured cardiac 
myocyte system. 
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CHAPTER 5 
SUMMARY AND CONCLUSION 
 
1. DOX induces significant increase of cardiac cell apoptosis, myocardial lesions, and 
cardiac dysfunction in ICR mice 3 days after administration. 
2. p53 protein is phosphorylated at Ser 15 in mouse hearts several hours after DOX 
injection, followed by the expression of downstream genes Bax, BclxL, and MDM2, 
indicating that the p53-dependent pathway plays a major role in DOX-induced cardiac 
cell apoptosis. 
3. The upstream events of the p53-dependent pathway are phosphorylation of ERK1/2 and 
p38 MAPKs, which phosphorylate p53 at Ser 15 in DOX-treated mouse hearts. 
4. PFT-α blocked DOX-induced cardiac cell apoptosis by inhibiting the expression of p53 
target genes and the activation of caspases-3 and -9. 
5. PFT-α has a protective ability against DOX-induced myocardial ultrastructural changes, 
serum CPK elevation, and cardiac dysfunction. 
6. MEL and 6-OH MEL protect cardiac function in DOX-perfused mouse hearts, as well as 
in mice 5 days after administration of DOX; they also improves the survival rate and 
attenuate the myocardial structural damages and CPK release in mice treated with DOX.   
7. MEL and 6-OH MEL significantly reduce cardiac cell apoptosis in DOX-treated mice. 
8. MEL protects MEL1a receptor-deficient as well as wild-type mice against DOX-induced 
cardiac dysfunction in isolated hearts, indicating that the MEL1a receptor is not 
important in its cardioprotective effect. 
9. Because 8-M-PDOT has no protective effects due to a lack of antioxidant activity, MEL 
and 6-OH MEL exert their actions primarily through their free radical scavenging ability. 
10. Neither PFT-α nor MEL compromises the anti-tumor potency of DOX on p53-null PC-3 
cancer cells.  
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APPENDICES 
 
 
APPENDIX A 
Components of Krebs-Henseleit Buffer Used in Heart Perfusion 
 
Table 6  Components of Krebs-Henseleit Bicarbonate Buffer 
Compounds  Formula Weight Concentration  Mass 
     (mM)  (g/L) 
NaCl         58.4        118   6.90 
Glucose      180.2          11    1.98 
NaHCO3        84.0          25   2.10 
KCl         74.56          4.7  0.35 
KH2PO4      136.09          1.2  0.16 
MgSO4      264.47          1.2  0.30 
CaCl2       147.02          2.0  0.29 
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APPENDIX B 
Abbreviations 
 
Apaf-1   apoptotic protease activating factor-1 
bp   base pair 
CFR   coronary flow rate 
CO   cardiac output 
CPK   creatine phosphokinase 
d   day 
DMSO   dimethyl sulfoxide 
DNA-PK  DNA-dependent protein kinase 
DOX   doxorubicin 
±dP/dt   first derivatives of LV pressure over time 
EDTA   ethylenediaminetetraacetic acid 
ERK   extracellular signal regulated kinase 
GAPDH  glyceraldehyde-3-phosphate dehydrogenase 
h   hour 
HR   heart rate 
6-OH MEL  6-hydroxymelatonin 
i.p.   intraperitoneal injection 
ISOL   in situ oligo ligation 
JNK   c-Jun N-terminal kinase  
LV   left ventricle 
LVDP   left ventricular developed pressure  
LVEDP  left ventricular end-diastolic pressure 
LVESP  left ventricular end-systolic pressure 
110 
MAPK   mitogen-activated protein kinase family 
MDM2  murine double minute clone 2 
MEK   MAPK kinase 
MEL   melatonin 
8-M-PDOT  8-methoxy-2-propionamidotetralin  
MnSOD  manganese superoxide dismutase 
NO   nitric oxide 
PARP   poly ADP-ribose polymerase 
PBS   phosphate-buffered saline 
PFT-α   pifithrin-α 
PTP   permeability transition pore 
ROS   reactive oxygen species 
RPA   ribonuclease protection assay 
SR   sarcoplasmic reticulum 
SV   stroke volume 
TNF-α   tumor necrosis factor-α 
TNFR   TNF-α receptor 
TUNEL  in situ terminal deoxynucleotidyl transferase mediated nick-end labeling 
wk   week 
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